{"questions": [{"id": "5a75eb6483b0d9ea66000004", "body": "What is Blount's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19370370", "http://www.ncbi.nlm.nih.gov/pubmed/20609637", "http://www.ncbi.nlm.nih.gov/pubmed/25932193", "http://www.ncbi.nlm.nih.gov/pubmed/15481748", "http://www.ncbi.nlm.nih.gov/pubmed/27583129", "http://www.ncbi.nlm.nih.gov/pubmed/12077670", "http://www.ncbi.nlm.nih.gov/pubmed/8657465", "http://www.ncbi.nlm.nih.gov/pubmed/23610758", "http://www.ncbi.nlm.nih.gov/pubmed/7670990", "http://www.ncbi.nlm.nih.gov/pubmed/9702674"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Correction of Blount's disease by a multi-axial external fixation system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "BACKGROUND: Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 426, "offsetInEndSection": 562, "text": "The purpose of this study was to determine the efficacy of the MAC system for the treatment of pediatric patients with Blount's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 562, "offsetInEndSection": 738, "text": "METHODS: A retrospective analysis of 17 consecutive patients with surgically corrected Blount's disease using the MAC system with tibial and fibular osteotomies was identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1315, "text": "RESULTS: The MAC system was able to correct the deformity of Blount's disease as measured by a decrease in the MAD (40.2 +/- 29.3 mm; P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1566, "text": "CONCLUSIONS: Correction of Blount's disease with osteotomy of the tibia and fibula as well as dynamic fixation with the MAC system achieved deformity correction as measured by radiographic indices with minimal intra- and post-operative complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1688, "text": "The ease of application and adjustment of the MAC system makes it an attractive option for Blount's deformity correction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "Can Blount's disease heal spontaneously?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "INTRODUCTION: In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}, {"offsetInBeginSection": 605, "offsetInEndSection": 1020, "text": "DISCUSSION: An alternative classification in three stages could then provide more suitable therapeutic indications: stage\u00a00: possible Blount's disease (patient older than 2.5 years); stage\u00a01: certain Blount's disease, active physis (+) (progressive varus, age >3 years, typical image with no epiphysiodesis bridging); stage\u00a02: certain Blount's disease, inactive physis (-) (superomedial tibial bony bridge).LEVEL OF", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}]}, {"id": "5a6a2dcab750ff4455000023", "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22666536", "http://www.ncbi.nlm.nih.gov/pubmed/17387144", "http://www.ncbi.nlm.nih.gov/pubmed/19374772", "http://www.ncbi.nlm.nih.gov/pubmed/22962458", "http://www.ncbi.nlm.nih.gov/pubmed/21619633", "http://www.ncbi.nlm.nih.gov/pubmed/22234889", "http://www.ncbi.nlm.nih.gov/pubmed/17989259"], "snippets": [{"offsetInBeginSection": 192, "offsetInEndSection": 436, "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 437, "offsetInEndSection": 650, "text": "To investigate the origin and evolution of this GRB, we sequenced and characterized the Hedgehog (Hh) loci from three invertebrate chordate amphioxus species, which share several early expression domains with Shh.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 916, "offsetInEndSection": 986, "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1275, "text": "After whole genome duplication in teleosts, GRBs, including HCNEs and target genes, were often maintained in both copies, while bystander genes were typically lost from one GRB, strongly suggesting that evolutionary pressure acts to keep the single-copy GRBs of higher vertebrates intact.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Transcriptional features of genomic regulatory blocks.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "BACKGROUND: Genomic regulatory blocks (GRBs) are chromosomal regions spanned by highly conserved non-coding elements (HCNEs), most of which serve as regulatory inputs of one target gene in the region.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772"}, {"offsetInBeginSection": 1538, "offsetInEndSection": 1706, "text": "CONCLUSIONS: GRB targets are genes with a number of unique features that are the likely cause of their ability to respond to regulatory inputs from very long distances.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "MOTIVATION: Genomic context analysis, also known as phylogenetic profiling, is widely used to infer functional interactions between proteins but rarely applied to non-coding cis-regulatory DNA elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22962458"}, {"offsetInBeginSection": 868, "offsetInEndSection": 969, "text": "This 'winner-takes-all' pattern suggests that UCNEs of a GRB function in a highly cooperative manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22962458"}, {"offsetInBeginSection": 788, "offsetInEndSection": 1029, "text": "In this paper, we therefore systematically investigate the regulatory landscape around conserved self-transcribed miRNAs (ST miRNAs), with their own known or computationally inferred promoters, by analyzing the hallmarks of GRB target genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633"}]}, {"id": "5a735cdc3b9d13c708000004", "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24025752"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 434, "offsetInEndSection": 599, "text": "During interval 2 two different doses of SYL040012 were administered to one eye on a daily basis to two separate groups of 12 subjects each, over a period of 7 days.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1040, "text": "Administration of SYL040012 over a period of 7 days reduced IOP values in 15 out of 24 healthy subjects regardless of the dose used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 1041, "offsetInEndSection": 1216, "text": "IOP decrease was statistically significant in response to one of the doses tested and responsiveness to SYL040012 seemed to be greater in individuals with higher baseline IOP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 852, "offsetInEndSection": 907, "text": "SYL040012 was not detected in plasma at any time point.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 344, "offsetInEndSection": 433, "text": "SYL040012 was administered to one eye as a single dose to six subjects during interval 1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 704, "offsetInEndSection": 741, "text": "SYL040012 was well tolerated locally.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 600, "offsetInEndSection": 703, "text": "The contralateral eye was evaluated but not administered and served as control for the tolerance study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 196, "offsetInEndSection": 343, "text": "The study was an open-label, controlled, single-center study comprised of two intervals that enrolled 30 healthy subjects having IOP below 21 mmHg.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}]}, {"id": "5a777ab9faa1ab7d2e00000a", "body": "What is the drug target(s) for Belsomra?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25336862"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862"}, {"offsetInBeginSection": 0, "offsetInEndSection": 31, "text": "Pharmaceutical approval update.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862"}]}, {"id": "5a8861eb8cb19eca6b000001", "body": "List the two most important synaptic markers.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22206847", "http://www.ncbi.nlm.nih.gov/pubmed/24205365", "http://www.ncbi.nlm.nih.gov/pubmed/27906174", "http://www.ncbi.nlm.nih.gov/pubmed/25755633", "http://www.ncbi.nlm.nih.gov/pubmed/26017624", "http://www.ncbi.nlm.nih.gov/pubmed/26776762", "http://www.ncbi.nlm.nih.gov/pubmed/22609570", "http://www.ncbi.nlm.nih.gov/pubmed/7783952", "http://www.ncbi.nlm.nih.gov/pubmed/21074556", "http://www.ncbi.nlm.nih.gov/pubmed/20540992"], "snippets": [{"offsetInBeginSection": 205, "offsetInEndSection": 431, "text": "The levels and distributions of some synaptic proteins have been found to be associated with dementia severity, even in the oldest-old, but the molecular and functional nature of these deficits have not been studied in detail.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 432, "offsetInEndSection": 659, "text": "The objective of this study was to assess the relationship of dementia with gene and protein expression of a panel of synaptic markers associated with different synaptic functions in young-, middle-, and oldest-old individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 660, "offsetInEndSection": 957, "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1400, "text": "The brains of persons with dementia evidenced significantly lower levels of gene and protein expression of synaptic markers regardless of age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1401, "offsetInEndSection": 1538, "text": "Importantly, dementia was associated with reductions in all measured synaptic markers irrespective of their role(s) in synaptic function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1539, "offsetInEndSection": 1846, "text": "Although other dementia-associated hallmarks of AD neuropathology (neuritic plaques and neurofibrillary tangles) become less prominent with increasing age, synaptic marker abnormalities in dementia remain constant with increasing age and may represent an independent substrate of dementia spanning all ages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Acute physiological stress promotes clustering of synaptic markers and alters spine morphology in the hippocampus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "GluA2-containing AMPA receptors and their association with protein kinase M zeta (PKM\u03b6) and post-synaptic density-95 (PSD-95) are important for learning, memory and synaptic plasticity processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}, {"offsetInBeginSection": 196, "offsetInEndSection": 453, "text": "Here we investigated these synaptic markers in the context of an acute 1h platform stress, which can disrupt spatial memory retrieval for a short-term memory on the object placement task and long-term memory retrieval on a well-learned radial arm maze task.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}, {"offsetInBeginSection": 454, "offsetInEndSection": 575, "text": "Acute stress increased serum corticosterone and elevated the expression of synaptic PKM\u03b6 while decreasing synaptic GluA2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}]}, {"id": "5a75ee7e83b0d9ea66000005", "body": "List symptoms of the Zieve's syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7110955", "http://www.ncbi.nlm.nih.gov/pubmed/2616809", "http://www.ncbi.nlm.nih.gov/pubmed/464793", "http://www.ncbi.nlm.nih.gov/pubmed/26203455", "http://www.ncbi.nlm.nih.gov/pubmed/548954", "http://www.ncbi.nlm.nih.gov/pubmed/11761804", "http://www.ncbi.nlm.nih.gov/pubmed/8819039", "http://www.ncbi.nlm.nih.gov/pubmed/966632"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "[Zieve's syndrome and acute alcoholic hepatitis (author's transl)].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 508, "offsetInEndSection": 638, "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "[Pathomechanism of Zieve's syndrome--observation of patients treated at the Infectious Disease Clinic, Medical Academy, in Bydgoszcz].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The views are presented on the pathological mechanism of Zieve's syndrome with description of 3 cases diagnosed in this Department.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 132, "offsetInEndSection": 247, "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 248, "offsetInEndSection": 311, "text": "This is possibly the cause of rare recognition of the syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 0, "offsetInEndSection": 18, "text": "[Zieve's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}, {"offsetInBeginSection": 140, "offsetInEndSection": 365, "text": "The Authors, after a short introduction regarding physiopathological problems, describe and subsequently examine on the clinical ground a recent personal observation, which had been mentioned for the rarene-s of this disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}]}, {"id": "5a7636d39e632bc066000004", "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27091472", "http://www.ncbi.nlm.nih.gov/pubmed/29028923", "http://www.ncbi.nlm.nih.gov/pubmed/29145625", "http://www.ncbi.nlm.nih.gov/pubmed/27591080", "http://www.ncbi.nlm.nih.gov/pubmed/26163694"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "BACKGROUND: The nature of somatic mutations observed in human tumors at single gene or genome-wide levels can reveal information on past carcinogenic exposures and mutational processes contributing to tumor development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 220, "offsetInEndSection": 484, "text": "While large amounts of sequencing data are being generated, the associated analysis and interpretation of mutation patterns that may reveal clues about the natural history of cancer present complex and challenging tasks that require advanced bioinformatics skills.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 697, "offsetInEndSection": 974, "text": "RESULTS: MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1155, "text": "MutSpec offers an accessible framework for building reproducible analysis pipelines, integrating existing methods and scripts developed in-house with publicly available R packages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 1561, "offsetInEndSection": 1806, "text": "CONCLUSIONS: MutSpec offers an easy-to-use graphical interface embedded in the popular Galaxy platform that can be used by researchers with limited programming or bioinformatics expertise to analyse mutation signatures present in cancer genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 1807, "offsetInEndSection": 1953, "text": "MutSpec can thus effectively assist in the discovery of complex mutational processes resulting from exogenous and endogenous carcinogenic insults.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Detecting presence of mutational signatures in cancer with confidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Motivation: Cancers arise as the result of somatically acquired changes in the DNA of cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 380, "offsetInEndSection": 484, "text": "These mutagenic processes often produce characteristic mutational patterns called mutational signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}]}, {"id": "5a8dc57ffcd1d6a10c000025", "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10828496", "http://www.ncbi.nlm.nih.gov/pubmed/23096238", "http://www.ncbi.nlm.nih.gov/pubmed/12959933", "http://www.ncbi.nlm.nih.gov/pubmed/8018339", "http://www.ncbi.nlm.nih.gov/pubmed/19628633", "http://www.ncbi.nlm.nih.gov/pubmed/11463790", "http://www.ncbi.nlm.nih.gov/pubmed/10679759", "http://www.ncbi.nlm.nih.gov/pubmed/23826298", "http://www.ncbi.nlm.nih.gov/pubmed/25209280", "http://www.ncbi.nlm.nih.gov/pubmed/26030739"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of various cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 122, "offsetInEndSection": 304, "text": "The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 305, "offsetInEndSection": 668, "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 669, "offsetInEndSection": 860, "text": "Of the 22 ovarian cancer specimens analyzed, 17 tumors ( approximately 77%) expressed mRNA for GRPR, 19 ( approximately 86%) showed NMBR mRNA and six ( approximately 27%) revealed BRS-3 mRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1006, "text": "Thus, 14 of 22 specimens ( approximately 64%) expressed mRNAs for both GRPR and NMBR, and five ( approximately 23%) expressed all three subtypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1097, "text": "The expression of GRPR appeared to be greater in poorly differentiated ovarian carcinomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1423, "text": "mRNA for both GRPR and NMBR was also detected in OV-1063 and UCI-107 human ovarian cancer xenografts, but BRS-3 was found only in OV-1063, which originated from a metastatic tumor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1424, "offsetInEndSection": 1598, "text": "In addition, functional receptors for bombesin/GRP were found in eight of 11 ovarian cancer specimens investigated and in both ovarian cancer lines by receptor binding assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1731, "text": "Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}]}, {"id": "5a7602be83b0d9ea6600000f", "body": "Describe King\u2013Kopetzky syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16760737", "http://www.ncbi.nlm.nih.gov/pubmed/20512338", "http://www.ncbi.nlm.nih.gov/pubmed/25709171", "http://www.ncbi.nlm.nih.gov/pubmed/835533", "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "http://www.ncbi.nlm.nih.gov/pubmed/9777339", "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "http://www.ncbi.nlm.nih.gov/pubmed/23565480", "http://www.ncbi.nlm.nih.gov/pubmed/3144988"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Two brothers with Goldberg-Shprintzen syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Goldberg-Shprintzen syndrome is a rare autosomal recessive condition that describes the association of Hirschsprung disease with microcephaly, developmental delay and characteristic facies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 190, "offsetInEndSection": 308, "text": "We describe two brothers from a non-consanguineous family who have classical features of Goldberg-Shprintzen syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 309, "offsetInEndSection": 505, "text": "The novel findings in this instance are of foot anomalies including camptodactyly and clinodactyly of the 2nd to 4th toes, which have not been previously described in Goldberg-Shprintzen syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Ortner's syndrome as a presenting feature of giant cell arteritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Hoarseness due to left recurrent laryngeal nerve paralysis (LRLN) caused by identifiable cardiovascular disease is described as Ortner's syndrome or cardiovocal syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512338"}, {"offsetInBeginSection": 292, "offsetInEndSection": 401, "text": "This case report describe a patient with giant cell arteritis with initial presentation of Ortner's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "A rare newly described overgrowth syndrome with vascular malformations-Cloves syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171"}, {"offsetInBeginSection": 59, "offsetInEndSection": 82, "text": "A new genetic syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "We describe a syndrome of microcephaly, with extreme failure to thrive, (severe spasticity), kyphoscollosis, cataracts, and hip dysplasia in four siblings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533"}]}, {"id": "5a67c284b750ff4455000011", "body": "What is GenomeVIP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28522612"], "snippets": [{"offsetInBeginSection": 569, "offsetInEndSection": 789, "text": "Here, we introduce the Genome Variant Investigation Platform (GenomeVIP), an open-source framework for performing genomics variant discovery and annotation using cloud- or local high-performance computing infrastructure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 790, "offsetInEndSection": 1018, "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1231, "text": "GenomeVIP has been used for genomic analysis in large-data projects such as the TCGA PanCanAtlas and in other projects, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1422, "text": "Here, we demonstrate GenomeVIP's ability to provide high-confidence annotated somatic, germline, and de novo variants of potential biological significance using publicly available data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Identifying genomic variants is a fundamental first step toward the understanding of the role of inherited and acquired variation in disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 142, "offsetInEndSection": 348, "text": "The accelerating growth in the corpus of sequencing data that underpins such analysis is making the data-download bottleneck more evident, placing substantial burdens on the research community to keep pace.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 349, "offsetInEndSection": 568, "text": "As a result, the search for alternative approaches to the traditional \"download and analyze\" paradigm on local computing resources has led to a rapidly growing demand for cloud-computing solutions for genomics analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}, {"offsetInBeginSection": 6, "offsetInEndSection": 77, "text": "VIP: a cloud platform for genomic variant discovery and interpretation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612"}]}, {"id": "5a981e66fcd1d6a10c00002f", "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16762931", "http://www.ncbi.nlm.nih.gov/pubmed/15547646", "http://www.ncbi.nlm.nih.gov/pubmed/16505579", "http://www.ncbi.nlm.nih.gov/pubmed/12643148", "http://www.ncbi.nlm.nih.gov/pubmed/15940204", "http://www.ncbi.nlm.nih.gov/pubmed/21068471", "http://www.ncbi.nlm.nih.gov/pubmed/17125447", "http://www.ncbi.nlm.nih.gov/pubmed/17456293", "http://www.ncbi.nlm.nih.gov/pubmed/19108808", "http://www.ncbi.nlm.nih.gov/pubmed/15529616"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Does a diagnosis of metabolic syndrome have value in clinical practice?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "\"The metabolic syndrome\" is the name for a clustering of risk factors for cardiovascular disease and type 2 diabetes that are of metabolic origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 147, "offsetInEndSection": 304, "text": "These risk factors consist of atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a prothrombotic state, and a proinflammatory state.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 305, "offsetInEndSection": 417, "text": "There are 2 major, interacting causes of the metabolic syndrome-obesity and endogenous metabolic susceptibility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 418, "offsetInEndSection": 475, "text": "The latter typically is manifested by insulin resistance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 476, "offsetInEndSection": 626, "text": "The metabolic syndrome is accompanied by a 2-fold increase in the risk of cardiovascular disease and a 5-fold increase in the risk of type 2 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 627, "offsetInEndSection": 751, "text": "A clinical diagnosis of the metabolic syndrome is useful because it affects therapeutic strategy in patients at higher risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 752, "offsetInEndSection": 856, "text": "However, there are 2 views about the best therapeutic strategy for patients with the metabolic syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 857, "offsetInEndSection": 957, "text": "One view holds that each of the metabolic risk factors should be singled out and treated separately.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 958, "offsetInEndSection": 1099, "text": "The other view holds that greater emphasis should be given to implementing therapies that will reduce all of the risk factors simultaneously.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}]}, {"id": "5a76080683b0d9ea66000015", "body": "Is cilengitide effective for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21739168", "http://www.ncbi.nlm.nih.gov/pubmed/25163906", "http://www.ncbi.nlm.nih.gov/pubmed/24014381", "http://www.ncbi.nlm.nih.gov/pubmed/24442484", "http://www.ncbi.nlm.nih.gov/pubmed/23354807", "http://www.ncbi.nlm.nih.gov/pubmed/22866207", "http://www.ncbi.nlm.nih.gov/pubmed/22976135", "http://www.ncbi.nlm.nih.gov/pubmed/21417900", "http://www.ncbi.nlm.nih.gov/pubmed/17277694", "http://www.ncbi.nlm.nih.gov/pubmed/18616418"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 98, "offsetInEndSection": 210, "text": "Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 211, "offsetInEndSection": 334, "text": "This study was designed to evaluate the efficacy and tumor delivery of cilengitide in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 335, "offsetInEndSection": 618, "text": "Patients with recurrent glioblastoma who require a surgical resection for optimal clinical care received 3 intravenous doses of cilengitide at either 500 or 2000 mg (day -8, -4, -1) prior to undergoing tumor resection with corresponding blood samples for plasma to tumor comparisons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 749, "offsetInEndSection": 839, "text": "The study accrued 30 patients with recurrent glioblastoma, 26 were evaluable for efficacy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1342, "text": "This study provides evidence that with established dosing, cilengitide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent glioblastoma is modest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 1343, "offsetInEndSection": 1556, "text": "However, these results demonstrating drug delivery to tumor do support continued investigation of this agent as preliminary results from recent studies combining cilengitide with cytotoxic therapies are promising.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25163906"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "BACKGROUND: Cilengitide is a selective \u03b1v\u03b23 and \u03b1v\u03b25 integrin inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25163906"}, {"offsetInBeginSection": 73, "offsetInEndSection": 334, "text": "Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25163906"}]}, {"id": "5a6a3464b750ff4455000026", "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28088189", "http://www.ncbi.nlm.nih.gov/pubmed/19627599"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "MARS: improving multiple circular sequence alignment using refined sequences.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "BACKGROUND: A fundamental assumption of all widely-used multiple sequence alignment techniques is that the left- and right-most positions of the input sequences are relevant to the alignment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 478, "offsetInEndSection": 664, "text": "These scenarios are relevant, for instance, in the process of multiple sequence alignment of mitochondrial DNA, viroid, viral or other genomes, which have a circular molecular structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 665, "offsetInEndSection": 915, "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1039, "text": "RESULTS: We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1195, "text": "MARS was implemented in the C++ programming language as a program to compute the rotations (cyclic shifts) required to best align a set of input sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1469, "offsetInEndSection": 1725, "text": "Our results show, among others, that the average pairwise distance in the multiple sequence alignment of a dataset of widely-studied mitochondrial DNA sequences is reduced by around 5% when MARS is applied before a multiple sequence alignment is performed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1725, "offsetInEndSection": 1904, "text": "CONCLUSIONS: Analysing multiple sequences simultaneously is fundamental in biological research and multiple sequence alignment has been found to be a popular method for this task.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1905, "offsetInEndSection": 2019, "text": "Conventional alignment techniques cannot be used effectively when the position where sequences start is arbitrary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 2020, "offsetInEndSection": 2177, "text": "We present here a method, which can be used in conjunction with any multiple sequence alignment program, to address this problem effectively and efficiently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}]}, {"id": "5a74e9ad0384be955100000a", "body": "What is a SERM?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11795362", "http://www.ncbi.nlm.nih.gov/pubmed/24667357", "http://www.ncbi.nlm.nih.gov/pubmed/26343247", "http://www.ncbi.nlm.nih.gov/pubmed/12036407", "http://www.ncbi.nlm.nih.gov/pubmed/24930824", "http://www.ncbi.nlm.nih.gov/pubmed/20446043", "http://www.ncbi.nlm.nih.gov/pubmed/23925896", "http://www.ncbi.nlm.nih.gov/pubmed/18279543", "http://www.ncbi.nlm.nih.gov/pubmed/28978566", "http://www.ncbi.nlm.nih.gov/pubmed/15500393"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "What would be the properties of an ideal SERM?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 222, "offsetInEndSection": 414, "text": "The SERM tamoxifen acts as an estrogen antagonist in the breast in that it prevents and treats breast cancer, but it acts as an estrogen agonist in the endometrium, where it can induce cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1484, "text": "Data on the beneficial and adverse effects of estrogen and SERMs are reported along with an elaboration of the constellation of properties that would characterize an ideal SERM working through the ER.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 289, "offsetInEndSection": 425, "text": "PURPOSE: This study aimed to investigate whether treatment with a SERM enhances spinal fusion in an ovariectomized (OVX) rat model.STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 474, "offsetInEndSection": 747, "text": "METHODS: Female Sprague Dawley rats (n=90) were OVX or sham-operated, and randomized into three groups: control (sham-operated+fusion procedure+saline administration), OVX (OVX+fusion procedure+saline administration), and SERM (OVX+fusion procedure+administration of SERM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 1138, "offsetInEndSection": 1304, "text": "RESULTS: Bone mineral density and trabecular quality of the vertebral body were significantly higher in the SERM group compared with the OVX group 16 weeks after OVX.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 1305, "offsetInEndSection": 1454, "text": "The fusion rate and bone volume ratio were higher in the fusion bed of the SERM group compared with the OVX group 8 weeks after the fusion procedure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 1849, "offsetInEndSection": 1978, "text": "By contrast, the SERM group exhibited a compact bridging fusion mass within the fusion bed at 8 weeks after the fusion procedure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 0, "offsetInEndSection": 30, "text": "The search for the ideal SERM.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407"}, {"offsetInBeginSection": 486, "offsetInEndSection": 638, "text": "Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407"}]}, {"id": "5a7610ca83b0d9ea6600001b", "body": "What is the role of nimotuzumab in treatment of pontine glioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24696052", "http://www.ncbi.nlm.nih.gov/pubmed/25926743", "http://www.ncbi.nlm.nih.gov/pubmed/24847085", "http://www.ncbi.nlm.nih.gov/pubmed/23754473", "http://www.ncbi.nlm.nih.gov/pubmed/21171927", "http://www.ncbi.nlm.nih.gov/pubmed/23926436", "http://www.ncbi.nlm.nih.gov/pubmed/23043252"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 92, "offsetInEndSection": 228, "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 832, "offsetInEndSection": 958, "text": "Vinorelbine 25 mg/m(2) and nimotuzumab were given every other week thereafter until the tumor progressed or for up to 2 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1348, "text": "The nimotuzumab/vinorelbine combination was very well tolerated, with no acute side-effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Profile of nimotuzumab in the treatment of high-grade glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 499, "offsetInEndSection": 772, "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 773, "offsetInEndSection": 917, "text": "In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1076, "text": "As a result, multiple center randomized controlled Phase III clinical trials need to be conducted to confirm the efficacy and toxicity for nimotuzumab in HGG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24847085"}]}, {"id": "5a6a35b7b750ff4455000027", "body": "What is libgapmis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24564250"], "snippets": [{"offsetInBeginSection": 2286, "offsetInEndSection": 2371, "text": "The open-source code of libgapmis is available at http://www.exelixis-lab.org/gapmis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1143, "text": "RESULTS: In this article, we present libgapmis, a library for extending pairwise short-read alignments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 1938, "offsetInEndSection": 2028, "text": "CONCLUSIONS: We present libgapmis, a library for extending pairwise short-read alignments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1040, "text": "The fact that the reads are rather short and that the gap occurrence frequency observed in various studies is rather low suggest that aligning (parts of) those reads with a single gap is in fact desirable.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 2029, "offsetInEndSection": 2127, "text": "We show that libgapmis is better-suited and more efficient than existing algorithms for this task.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 464, "offsetInEndSection": 544, "text": "The seed-and-extend strategy is applied in most short-read alignment programmes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 1239, "offsetInEndSection": 1372, "text": "libgapmis is based on an algorithm computing a modified version of the traditional dynamic-programming matrix for sequence alignment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 2128, "offsetInEndSection": 2285, "text": "The importance of our contribution is underlined by the fact that the provided functions may be seamlessly integrated into any short-read alignment pipeline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "libgapmis: extending short-read alignments.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}, {"offsetInBeginSection": 545, "offsetInEndSection": 834, "text": "After aligning a substring of the reference sequence against the high-quality prefix of a short read--the seed--an important problem is to find the best possible alignment between a substring of the reference sequence succeeding and the remaining suffix of low quality of the read--extend.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250"}]}, {"id": "5a76016683b0d9ea6600000d", "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19458618", "http://www.ncbi.nlm.nih.gov/pubmed/25738006", "http://www.ncbi.nlm.nih.gov/pubmed/1838097", "http://www.ncbi.nlm.nih.gov/pubmed/19212162", "http://www.ncbi.nlm.nih.gov/pubmed/11399108", "http://www.ncbi.nlm.nih.gov/pubmed/28959732", "http://www.ncbi.nlm.nih.gov/pubmed/26243569", "http://www.ncbi.nlm.nih.gov/pubmed/2880544"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 272, "offsetInEndSection": 494, "text": "One such gene is Down's syndrome candidate region-1 (DSCR1, also known as RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signalling by the calcineurin pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 495, "offsetInEndSection": 599, "text": "Here we show that DSCR1 is increased in Down's syndrome tissues and in a mouse model of Down's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1094, "text": "We also provide evidence that attenuation of calcineurin activity by DSCR1, together with another chromosome 21 gene Dyrk1a, may be sufficient to markedly diminish angiogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1335, "text": "These data provide a mechanism for the reduced cancer incidence in Down's syndrome and identify the calcineurin signalling pathway, and its regulators DSCR1 and DYRK1A, as potential therapeutic targets in cancers arising in all individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006"}, {"offsetInBeginSection": 66, "offsetInEndSection": 235, "text": "About 3% of cases of Downs syndrome occur due to Robertsonian translocation, most commonly t (14; 21), other types of translocations are very rare cause of the syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "[Human alpha-satellite DNA specific to chromosomes 13 and 21: use for the analysis of polymorphism of acrocentric chromosomes and the origin of the additional chromosome 21 in Down's syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}, {"offsetInBeginSection": 524, "offsetInEndSection": 601, "text": "the number of satellite DNA copies) both between and within chromosome pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}, {"offsetInBeginSection": 802, "offsetInEndSection": 998, "text": "Analysis of individual distribution of satellite between homologues of chromosome 21 provides new possibilities for determination of the origin of extra chromosome in the patients with trisomy 21.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}]}, {"id": "5a7615af83b0d9ea6600001f", "body": "Is vorinostat effective for glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20135194", "http://www.ncbi.nlm.nih.gov/pubmed/24576944", "http://www.ncbi.nlm.nih.gov/pubmed/29016887", "http://www.ncbi.nlm.nih.gov/pubmed/19307505", "http://www.ncbi.nlm.nih.gov/pubmed/23996800", "http://www.ncbi.nlm.nih.gov/pubmed/22028388", "http://www.ncbi.nlm.nih.gov/pubmed/22086447", "http://www.ncbi.nlm.nih.gov/pubmed/24838514", "http://www.ncbi.nlm.nih.gov/pubmed/22090453", "http://www.ncbi.nlm.nih.gov/pubmed/22923449"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 197, "offsetInEndSection": 385, "text": "What makes these agents particularly attractive is their capacity to enhance the activity of commonly used cytotoxics in cancer therapy, including both chemotherapy and ionizing radiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 386, "offsetInEndSection": 693, "text": "As recent investigations suggest HDAC inhibitors may potentiate the cytotoxicity of topoisomerase inhibitors, which continue to be a commonly used class of agents in the treatment of glioblastoma, we performed preclinical studies to determine if this combination may be a promising strategy in glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 694, "offsetInEndSection": 862, "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1255, "text": "Vorinostat enhanced the cytotoxicity of SN38 in glioblastoma cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 1484, "offsetInEndSection": 1680, "text": "These results indicate vorinostat enhances the cytotoxicity of SN38 in glioblastoma cell lines, suggesting this combination may be a worthwhile strategy to test in the context of a clinical trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}, {"offsetInBeginSection": 709, "offsetInEndSection": 826, "text": "A single case report of dapsone-induced hemolytic anemia in a patient with glioblastoma multiforme has been reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}]}, {"id": "5a6a7869b750ff4455000028", "body": "Describe SNP2TFBS", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27899579"], "snippets": [{"offsetInBeginSection": 1058, "offsetInEndSection": 1101, "text": "Homepage: http://ccg.vital-it.ch/snp2tfbs/.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 586, "offsetInEndSection": 761, "text": "These data files are regenerated at regular intervals by an automatic procedure that takes as input a reference genome, a comprehensive SNP catalogue and a collection of PWMs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "SNP2TFBS - a database of regulatory SNPs affecting predicted transcription factor binding site affinity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "SNP2TFBS is a computational resource intended to support researchers investigating the molecular mechanisms underlying regulatory variation in the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 762, "offsetInEndSection": 1057, "text": "SNP2TFBS is also accessible over a web interface, enabling users to view the information provided for an individual SNP, to extract SNPs based on various search criteria, to annotate uploaded sets of SNPs or to display statistics about the frequencies of binding sites affected by selected SNPs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 441, "offsetInEndSection": 585, "text": "A SNP's effect on TF binding is estimated based on a position weight matrix (PWM) model for the binding specificity of the corresponding factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}, {"offsetInBeginSection": 161, "offsetInEndSection": 440, "text": "The database essentially consists of a collection of text files providing specific annotations for human single nucleotide polymorphisms (SNPs), namely whether they are predicted to abolish, create or change the affinity of one or several transcription factor (TF) binding sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579"}]}, {"id": "5a7706b79e632bc066000009", "body": "What is trismus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26098612", "http://www.ncbi.nlm.nih.gov/pubmed/26058916", "http://www.ncbi.nlm.nih.gov/pubmed/23193958", "http://www.ncbi.nlm.nih.gov/pubmed/20236743", "http://www.ncbi.nlm.nih.gov/pubmed/24985733", "http://www.ncbi.nlm.nih.gov/pubmed/24669774", "http://www.ncbi.nlm.nih.gov/pubmed/22632890", "http://www.ncbi.nlm.nih.gov/pubmed/28122104", "http://www.ncbi.nlm.nih.gov/pubmed/27461633", "http://www.ncbi.nlm.nih.gov/pubmed/27627138"], "snippets": [{"offsetInBeginSection": 82, "offsetInEndSection": 145, "text": "A mouth opening of 35 mm or less should be regarded as trismus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 146, "offsetInEndSection": 297, "text": "Aim of this study was to review the etiopathogenesis, incidence, treatment and prevention of trismus in patients with head and neck cancer.OBJECTIVE OF", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 298, "offsetInEndSection": 399, "text": "REVIEW: Trismus is frequently seen in patients suffering from malignant tumours of the head and neck.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 400, "offsetInEndSection": 560, "text": "The reported prevalence of trismus in those patients varies considerably in the literature and ranges from 0 to 100% depending on the tumour site and extension.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 672, "offsetInEndSection": 851, "text": "When a patient presents with trismus after tumour treatment, it is important to determine whether the trismus is the result of the treatment, or is the first sign of a recurrence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1308, "text": "The use of intensity-modulated RT seems to lower the percentage and severity of RT-induced trismus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 1309, "offsetInEndSection": 1404, "text": "Treatment of trismus can be conservative (with either medical or physical therapy) or surgical.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 1514, "offsetInEndSection": 1600, "text": "The prevention of trismus, rather than its treatment, is the most important objective.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 260, "offsetInEndSection": 398, "text": "Radiotherapy in the head and neck area is identified as one of the most frequent causes of trismus in head and neck cancer (HNC) patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916"}, {"offsetInBeginSection": 399, "offsetInEndSection": 453, "text": "Currently, there is no standard treatment for trismus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916"}]}, {"id": "5a67ab79b750ff445500000b", "body": "CURB65 score is used for stratification of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28168816", "http://www.ncbi.nlm.nih.gov/pubmed/20529344", "http://www.ncbi.nlm.nih.gov/pubmed/20920140", "http://www.ncbi.nlm.nih.gov/pubmed/18304365", "http://www.ncbi.nlm.nih.gov/pubmed/16928720", "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "http://www.ncbi.nlm.nih.gov/pubmed/24931899"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "INTRODUCTION: Pneumonia is an inflammatory disease caused by micro-organisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 78, "offsetInEndSection": 178, "text": "The pneumonia severity index (PSI) and CURB_65 scores are widely used to predict the mortality risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1170, "text": "The lactate level, PSI score and CURB_65 scores are good predictors for mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 1171, "offsetInEndSection": 1236, "text": "We can use them in emergency departments for risk stratification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 517, "offsetInEndSection": 857, "text": "We compared the prognostic accuracy of these biomarkers with the pneumonia severity index (PSI) and CURB65 (Confusion, Urea, Respiratory rate, Blood pressure, Age 65) score to predict serious complications defined as death, ICU admission and disease-specific complications using receiver operating curves (ROC) and reclassification methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1226, "text": "ProADM or proET1 alone had stronger discriminatory powers than the PSI or CURB65 score or any of either score components to predict serious complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140"}, {"offsetInBeginSection": 229, "offsetInEndSection": 318, "text": "The CURB65 score was developed to predict mortality risk in community acquired pneumonia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140"}, {"offsetInBeginSection": 319, "offsetInEndSection": 420, "text": "A retrospective study found that this score was also associated with mortality in COPD exacerbations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140"}, {"offsetInBeginSection": 421, "offsetInEndSection": 524, "text": "We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140"}]}, {"id": "5a6cfe27b750ff4455000029", "body": "What is SMiLE-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28092692"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "SMiLE-seq identifies binding motifs of single and dimeric transcription factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 127, "offsetInEndSection": 303, "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 304, "offsetInEndSection": 503, "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 504, "offsetInEndSection": 621, "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Resolving the DNA-binding specificities of transcription factors (TFs) is of critical value for understanding gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 622, "offsetInEndSection": 746, "text": "All tested TFs yielded DNA-binding models with predictive power comparable to or greater than that of other in vitro assays.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 747, "offsetInEndSection": 923, "text": "De novo motif discovery on all JUN-FOS heterodimers and several nuclear receptor-TF complexes provided novel insights into partner-specific heterodimer DNA-binding preferences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1069, "text": "We also successfully analyzed the DNA-binding properties of uncharacterized human C2H2 zinc-finger proteins and validated several using ChIP-exo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}]}, {"id": "5a77072c9e632bc06600000a", "body": "What is craniosynostosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29093661", "http://www.ncbi.nlm.nih.gov/pubmed/17980312", "http://www.ncbi.nlm.nih.gov/pubmed/27622416", "http://www.ncbi.nlm.nih.gov/pubmed/27226847", "http://www.ncbi.nlm.nih.gov/pubmed/26910679", "http://www.ncbi.nlm.nih.gov/pubmed/24071792", "http://www.ncbi.nlm.nih.gov/pubmed/20108486", "http://www.ncbi.nlm.nih.gov/pubmed/28623672", "http://www.ncbi.nlm.nih.gov/pubmed/28654618", "http://www.ncbi.nlm.nih.gov/pubmed/18344207"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Craniosynostosis is a heterogeneous condition caused by the premature fusion of cranial sutures, occurring mostly as an isolated anomaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661"}, {"offsetInBeginSection": 214, "offsetInEndSection": 360, "text": "In about 15-30% of cases craniosynostosis occurs in association with other physical anomalies and it is referred to as syndromic craniosynostosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1644, "text": "We observed that craniosynostosis is uncommon on average in these conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 29, "text": "Genetics of craniosynostosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 158, "offsetInEndSection": 239, "text": "Craniosynostosis can be divided into two main groups: syndromic and nonsyndromic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 240, "offsetInEndSection": 358, "text": "Nonsyndromic craniosynostosis is typically an isolated finding that is classified according to the suture(s) involved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 359, "offsetInEndSection": 542, "text": "Syndromic craniosynostosis is associated with various dysmorphisms involving the face, skeleton, nervous system, and other anomalies and is usually accompanied by developmental delay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 543, "offsetInEndSection": 603, "text": "More than 180 syndromes exist that contain craniosynostosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 604, "offsetInEndSection": 720, "text": "Secondary effects of craniosynostosis may include vision problems and increased intracranial pressure, among others.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 721, "offsetInEndSection": 869, "text": "The molecular basis of many types of syndromic craniosynostosis is known, and diagnostic testing strategies will often lead to a specific diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}]}, {"id": "5a67b152b750ff445500000e", "body": "Describe nursemaid's elbow injury.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19657259", "http://www.ncbi.nlm.nih.gov/pubmed/27294496", "http://www.ncbi.nlm.nih.gov/pubmed/21317693", "http://www.ncbi.nlm.nih.gov/pubmed/11153321", "http://www.ncbi.nlm.nih.gov/pubmed/7773660", "http://www.ncbi.nlm.nih.gov/pubmed/7560033"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Nursemaid's elbow: a preventable pediatric injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 144, "offsetInEndSection": 227, "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 228, "offsetInEndSection": 323, "text": "This injury occurs when the radial head subluxates from its normal position at the elbow joint.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 324, "offsetInEndSection": 444, "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 445, "offsetInEndSection": 605, "text": "Prevention of nursemaid's elbow in children may be accomplished with education of parents, daycare workers, and teachers on the mechanism of this common injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Elbow Pain After a Fall: Nursemaid's Elbow or Fracture?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 295, "offsetInEndSection": 375, "text": "A common clinical mistake is to treat all elbow injuries as a nursemaid's elbow.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 472, "offsetInEndSection": 661, "text": "Occult fractures, also known as \"hairline\" elbow fractures, may not be visible on initial X-rays, but clues to the diagnosis, especially the posterior fat pad, can be helpful in evaluation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 662, "offsetInEndSection": 802, "text": "When an occult fracture is suspected based on history and radiographic findings, the patient's elbow should be immobilized, not manipulated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}]}, {"id": "5a6d08d5b750ff445500002c", "body": "Which stapled peptide has been designed to target Ctf4?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28815832"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Targeting the Genome-Stability Hub Ctf4 by Stapled-Peptide Design.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 156, "offsetInEndSection": 312, "text": "The Ctf4/AND-1 protein hub, which links DNA replication, repair, and chromosome segregation, represents a novel target for the synthetic lethality approach.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 313, "offsetInEndSection": 490, "text": "Herein, we report the design, optimization, and validation of double-click stapled peptides encoding the Ctf4-interacting peptide (CIP) of the replicative helicase subunit Sld5.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 491, "offsetInEndSection": 635, "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 636, "offsetInEndSection": 749, "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 750, "offsetInEndSection": 867, "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 868, "offsetInEndSection": 999, "text": "Our study provides proof-of-principle evidence for the development of small-molecule inhibitors of the human CTF4 orthologue AND-1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The exploitation of synthetic lethality by small-molecule targeting of pathways that maintain genomic stability is an attractive chemotherapeutic approach.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}]}, {"id": "5a773c50faa1ab7d2e000002", "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22102693", "http://www.ncbi.nlm.nih.gov/pubmed/21338441"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 261, "offsetInEndSection": 409, "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 410, "offsetInEndSection": 562, "text": "Strikingly, primary embryo fibroblasts from ATF4-deficient mice were resistant to transformation by coexpression of H-ras(V12) and SV40 large T antigen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 772, "offsetInEndSection": 888, "text": "Elevated levels of ATF4 were sufficient to suppress expression of these proteins and drive oncogenic transformation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1155, "text": "Our findings define a central function for ATF4 in promoting oncogenic transformation by suppressing a central pathway of cellular senescence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 234, "offsetInEndSection": 414, "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 518, "offsetInEndSection": 640, "text": "Tribbles proteins are also involved in a series of non-neoplastic disorders including metabolic and neurological diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1201, "text": "Although the molecular function of tribbles is still under investigation, the research on tribbles in cellular processes, homeostasis of organisms and human diseases will provide valuable information for therapy of cancer as well as non-neoplastic disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}]}, {"id": "5a68eabab750ff4455000015", "body": "Is there an association between Klinefelter syndrome and breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22274665", "http://www.ncbi.nlm.nih.gov/pubmed/16106025", "http://www.ncbi.nlm.nih.gov/pubmed/1690312", "http://www.ncbi.nlm.nih.gov/pubmed/7841064", "http://www.ncbi.nlm.nih.gov/pubmed/9283592", "http://www.ncbi.nlm.nih.gov/pubmed/21246928", "http://www.ncbi.nlm.nih.gov/pubmed/3111653", "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "http://www.ncbi.nlm.nih.gov/pubmed/23464700", "http://www.ncbi.nlm.nih.gov/pubmed/20698148"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "OBJECTIVE: We report a case of a patient with Klinefelter syndrome and glaucoma.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 197, "offsetInEndSection": 334, "text": "Besides reduced fertility, no characteristic physical or behavioral symptoms for Klinefelter syndrome were found on clinical examination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "DISCUSSION: Klinefelter syndrome is the most common cause of male hypogonadism with a variety of clinical signs and symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 874, "offsetInEndSection": 999, "text": "Several other classical features of the syndrome including mental retardation, gynecomastia, and breast cancer are described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1088, "text": "However, the association between Klinefelter syndrome and ocular manifestations is rare.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1213, "text": "CONCLUSIONS: : Glaucoma or in fact any other ocular manifestations associated with Klinefelter syndrome are rarely described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1349, "text": "Here, we report a case of glaucoma and its treatment combining trabeculotomy and trabeculectomy in a patient with Klinefelter syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "BACKGROUND: Men with Klinefelter syndrome have one or more extra X chromosomes and have endocrine abnormalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025"}, {"offsetInBeginSection": 113, "offsetInEndSection": 281, "text": "Case reports have led to suggestions that men with Klinefelter syndrome have elevated risks of several cancers, but published cohort studies have been relatively small.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025"}]}, {"id": "5a6d1733b750ff4455000030", "body": "Which resource contains accurate enhancer predictions in the developing limb?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28827824"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Limb-Enhancer Genie: An accessible resource of accurate enhancer predictions in the developing limb.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 415, "offsetInEndSection": 607, "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 608, "offsetInEndSection": 854, "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 142, "offsetInEndSection": 236, "text": "However, reliance on single chromatin marks leads to high rates of false-positive predictions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 237, "offsetInEndSection": 414, "text": "More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 1015, "offsetInEndSection": 1185, "text": "Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 1285, "offsetInEndSection": 1589, "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1014, "text": "By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1284, "text": "We demonstrate the utility of our approach through in vivo validation of newly predicted elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}]}, {"id": "5a7877c0faa1ab7d2e00000c", "body": "What is the first line treatment for sarcoidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26357609", "http://www.ncbi.nlm.nih.gov/pubmed/28696638", "http://www.ncbi.nlm.nih.gov/pubmed/26478443", "http://www.ncbi.nlm.nih.gov/pubmed/26419478", "http://www.ncbi.nlm.nih.gov/pubmed/26120005", "http://www.ncbi.nlm.nih.gov/pubmed/26330764", "http://www.ncbi.nlm.nih.gov/pubmed/23196575", "http://www.ncbi.nlm.nih.gov/pubmed/27598883", "http://www.ncbi.nlm.nih.gov/pubmed/27846819", "http://www.ncbi.nlm.nih.gov/pubmed/10719453"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 20, "text": "Hepatic Sarcoidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Sarcoidosis is a multisystem disease characterized by the presence of non-caseating granulomas in affected organs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 182, "offsetInEndSection": 277, "text": "However, hepatic involvement is also common in sarcoidosis, occurring in up to 70% of patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 571, "offsetInEndSection": 667, "text": "Portal hypertension and cirrhosis are complications linked to long-standing hepatic sarcoidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 727, "offsetInEndSection": 835, "text": "It is important to differentiate hepatic sarcoidosis from other autoimmune and granulomatous liver diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 836, "offsetInEndSection": 891, "text": "Not all cases of hepatic sarcoidosis require treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 892, "offsetInEndSection": 992, "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1060, "text": "Various immunosuppressant agents can be used as second line agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Update on the treatment of sarcoidosis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Sarcoidosis is a granulomatous disease characterized by variable manifestations and course.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638"}]}, {"id": "5a68f005b750ff4455000016", "body": "Which personality disorder is treated using dialectical behavior therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16173357", "http://www.ncbi.nlm.nih.gov/pubmed/17496179", "http://www.ncbi.nlm.nih.gov/pubmed/9603574", "http://www.ncbi.nlm.nih.gov/pubmed/7977884", "http://www.ncbi.nlm.nih.gov/pubmed/15930077", "http://www.ncbi.nlm.nih.gov/pubmed/19755574", "http://www.ncbi.nlm.nih.gov/pubmed/20579633", "http://www.ncbi.nlm.nih.gov/pubmed/27642799", "http://www.ncbi.nlm.nih.gov/pubmed/18186120", "http://www.ncbi.nlm.nih.gov/pubmed/25373068"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "A proposed trial of dialectical behavior therapy and trauma model therapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Dissociative identity disorder and borderline personality disorder resemble each other in trauma histories and comorbidity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 124, "offsetInEndSection": 176, "text": "Each disorder is frequently comorbid with the other.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 177, "offsetInEndSection": 340, "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 463, "offsetInEndSection": 671, "text": "The subject groups are borderline personality disorder without dissociative identity disorder; dissociative identity disorder without borderline personality disorder; and both conditions present concurrently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 672, "offsetInEndSection": 765, "text": "Subjects would be randomized to receive Dialectical Behavior Therapy or Trauma Model Therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 766, "offsetInEndSection": 994, "text": "Such a study could provide answers to controversies in the field about a better treatment approach for dissociative identity disorder and potentially could broaden and strengthen the indications for Dialectical Behavior Therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "OBJECTIVE: The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}, {"offsetInBeginSection": 241, "offsetInEndSection": 405, "text": "METHOD: The authors present a patient with borderline personality disorder treated by a resident using DBT, along with perspectives from the resident's supervisors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}]}, {"id": "5a6d186db750ff4455000031", "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028947", "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "http://www.ncbi.nlm.nih.gov/pubmed/17582322", "http://www.ncbi.nlm.nih.gov/pubmed/28821666", "http://www.ncbi.nlm.nih.gov/pubmed/16766712", "http://www.ncbi.nlm.nih.gov/pubmed/19026749"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Dlx1 and Dlx2 Promote Interneuron GABA Synthesis, Synaptogenesis, and Dendritogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 105, "offsetInEndSection": 210, "text": "Here, using conditional Dlx1, Dlx2, and Dlx1&2 knockouts (CKOs), we defined their roles in specific CINs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 292, "offsetInEndSection": 421, "text": "We provide evidence that DLX2 directly drives Gad1, Gad2, and Vgat expression, and show that mutants had reduced mIPSC amplitude.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 422, "offsetInEndSection": 533, "text": "In addition, the mutants formed fewer GABAergic synapses on excitatory neurons and had reduced mIPSC frequency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 534, "offsetInEndSection": 641, "text": "Furthermore, Dlx1/2 CKO had hypoplastic dendrites, fewer excitatory synapses, and reduced excitatory input.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Dlx homeobox genes promote cortical interneuron migration from the basal forebrain by direct repression of the semaphorin receptor neuropilin-2.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Dlx homeobox genes play an important role in vertebrate forebrain development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}, {"offsetInBeginSection": 79, "offsetInEndSection": 241, "text": "Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}, {"offsetInBeginSection": 242, "offsetInEndSection": 341, "text": "However, the molecular basis for these defects downstream of loss of Dlx1/Dlx2 function is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}]}, {"id": "5a79d0b8faa1ab7d2e00000d", "body": "What cellular process are okazaki fragments associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21278448", "http://www.ncbi.nlm.nih.gov/pubmed/14693726", "http://www.ncbi.nlm.nih.gov/pubmed/28159842", "http://www.ncbi.nlm.nih.gov/pubmed/23451868", "http://www.ncbi.nlm.nih.gov/pubmed/25814667", "http://www.ncbi.nlm.nih.gov/pubmed/19779567", "http://www.ncbi.nlm.nih.gov/pubmed/24035200", "http://www.ncbi.nlm.nih.gov/pubmed/227871", "http://www.ncbi.nlm.nih.gov/pubmed/16427006", "http://www.ncbi.nlm.nih.gov/pubmed/21441898"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Completion of lagging strand DNA synthesis requires processing of up to 50 million Okazaki fragments per cell cycle in mammalian cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 136, "offsetInEndSection": 262, "text": "Even in yeast, the Okazaki fragment maturation happens approximately a million times during a single round of DNA replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 263, "offsetInEndSection": 368, "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 369, "offsetInEndSection": 506, "text": "During this process, primase-synthesized RNA/DNA primers are removed, and Okazaki fragments are joined into an intact lagging strand DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 741, "offsetInEndSection": 819, "text": "Recent findings reveal that Okazaki fragment maturation is highly coordinated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 820, "offsetInEndSection": 999, "text": "The dynamic interactions of polymerase \u03b4, FEN1 and DNA ligase I with proliferating cell nuclear antigen allow these enzymes to act sequentially during Okazaki fragment maturation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1265, "text": "We also discuss studies using mutant mouse models that suggest two distinct cancer etiological mechanisms arising from defects in different steps of Okazaki fragment maturation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The protein components and mechanism of eukaryotic Okazaki fragment maturation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693726"}, {"offsetInBeginSection": 207, "offsetInEndSection": 330, "text": "Frequent priming of the discontinuous strand results in the formation of many small segments, designated Okazaki fragments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693726"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1389, "text": "Properties of the major protein components in this process will be discussed, and the validity of each model as a true representation of Okazaki fragment processing will be critically evaluated in this review.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693726"}]}, {"id": "5a68f633b750ff4455000019", "body": "Is creatinine assessment included in the MELD score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27480755", "http://www.ncbi.nlm.nih.gov/pubmed/15482344", "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "http://www.ncbi.nlm.nih.gov/pubmed/24601755", "http://www.ncbi.nlm.nih.gov/pubmed/22380485", "http://www.ncbi.nlm.nih.gov/pubmed/20827408", "http://www.ncbi.nlm.nih.gov/pubmed/17370333", "http://www.ncbi.nlm.nih.gov/pubmed/22178107", "http://www.ncbi.nlm.nih.gov/pubmed/27779785", "http://www.ncbi.nlm.nih.gov/pubmed/18482269"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480755"}, {"offsetInBeginSection": 1321, "offsetInEndSection": 1397, "text": "A MELD score >12 selects a subgroup of patients with a higher risk of death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480755"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "BACKGROUND: The model for end-stage liver disease (MELD) score is a useful tool to assess prognosis in critically ill cirrhotic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 273, "offsetInEndSection": 371, "text": "The creatinine serum level is an important predictor of survival in patients with liver cirrhosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 371, "offsetInEndSection": 530, "text": "AIMS: To evaluate and compare the short-term prognostic accuracy of the CTP, the creatinine-modified CTP, and the MELD scores in patients with liver cirrhosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 530, "offsetInEndSection": 639, "text": "METHODS: CTP, creatinine-modified CTP, and MELD scores were calculated in a cohort of 145 cirrhotic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 640, "offsetInEndSection": 861, "text": "The creatinine-modified CTP was calculated as follows: we assessed the mean creatinine serum level and standard deviation (SD) of the 145 study patients, then assigned a score of 1 to patients with creatinine serum levels", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 862, "offsetInEndSection": 986, "text": "RESULTS: The creatinine-modified CTP score showed better prognostic accuracy as compared with the traditional CTP (P=0.049).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1181, "text": "However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}]}, {"id": "5a6d196db750ff4455000032", "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27710791"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Subpallial Enhancer Transgenic Lines: a Data and Tool Resource to Study Transcriptional Regulation of GABAergic Cell Fate.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Elucidating the transcriptional circuitry controlling forebrain development requires an understanding of\u00a0enhancer activity and regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791"}, {"offsetInBeginSection": 139, "offsetInEndSection": 200, "text": "We generated stable transgenic mouse lines that express CreER", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791"}]}, {"id": "5a79d195faa1ab7d2e00000e", "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24240659"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Diversity of oat varieties in eliciting the early inflammatory events in celiac disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "PURPOSE: Celiac disease (CD) is an autoimmune enteropathy, triggered by dietary gluten.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 276, "offsetInEndSection": 451, "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 589, "offsetInEndSection": 819, "text": "METHODS: K562(S) cells agglutination, transepithelial electrical resistance of T84-cell monolayers, intracellular levels of TG2 and phosphorylated form of protein 42-44 in T84 cells were the early gliadin-dependent events studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1119, "text": "The ability of a cultivar to activate the above-described events was associated with the electrophoretic pattern of oat proteins and their reactivity to anti-gliadin antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 1119, "offsetInEndSection": 1240, "text": "CONCLUSION: We found significant differences among oat cultivars in eliciting the TG2-mediated events of CD inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 819, "offsetInEndSection": 941, "text": "RESULTS: The results showed that the Nave oat cultivar elicited these events, whereas Irina and Potenza varieties did not.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 452, "offsetInEndSection": 589, "text": "In addition, we compared this capability with the electrophoresis pattern of peptic-tryptic digests of the proteins of the oat cultivars.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 88, "offsetInEndSection": 136, "text": "The only treatment is a strict gluten-free diet.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 137, "offsetInEndSection": 275, "text": "Oats are included in the list of gluten-free ingredients by European Regulation, but the safety of oats in CD is still a matter of debate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}]}, {"id": "5a68f965b750ff445500001a", "body": "Clue cells are characteristics to which causative bacteria of vaginitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3497132", "http://www.ncbi.nlm.nih.gov/pubmed/6610607", "http://www.ncbi.nlm.nih.gov/pubmed/12838684", "http://www.ncbi.nlm.nih.gov/pubmed/10932748"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Non-specific vaginitis or vaginitis of undetermined aetiology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 111, "offsetInEndSection": 158, "text": "The specific aetiologies of vaginitis are many.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 159, "offsetInEndSection": 343, "text": "One of the most common entities, however, is \"non-specific vaginitis\" which can be subdivided into: Gardnerella vaginitis, anaerobic vaginosis, and vaginitis of undetermined aetiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 344, "offsetInEndSection": 473, "text": "The role of Gardnerella as a causative agent for vaginitis has been studied in depth but its specific role remains controversial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 474, "offsetInEndSection": 638, "text": "Anaerobic vaginosis can be diagnosed by noting on microscopic examination the presence of clue cells, free-floating bacteria and numerous white blood cells (WBC's).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 639, "offsetInEndSection": 720, "text": "Culturing an aliquot of the vaginal discharge reveals a high number of anaerobes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 823, "offsetInEndSection": 999, "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1104, "text": "The microbiology of this vaginitis includes many facultative Gram-negative rods and Gram-positive cocci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1304, "text": "This condition does not respond to the usual antibiotic therapies employed in treating bacterial vaginitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Gardnerella-associated vaginitis and anaerobic bacteria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6610607"}]}, {"id": "5a6d1db1b750ff4455000033", "body": "What is the purpose of the FaceBase consortium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21458441", "http://www.ncbi.nlm.nih.gov/pubmed/27287806", "http://www.ncbi.nlm.nih.gov/pubmed/26168040"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The FaceBase Consortium: a comprehensive program to facilitate craniofacial research.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1291, "text": "The FaceBase website (http://www.facebase.org) will serve as a web home for these efforts, providing interactive tools for exploring these datasets, together with discussion forums and other services to support and foster collaboration within the craniofacial research community.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The FaceBase Consortium: a comprehensive resource for craniofacial researchers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 0, "offsetInEndSection": 521, "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 522, "offsetInEndSection": 924, "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1119, "text": "The integrated data visualization tools, faceted search infrastructure, and curation provided by the FaceBase Hub offer flexible and intuitive ways to interact with these multidisciplinary data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The NIH FACEBASE consortium was established in part to create a central resource for craniofacial researchers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040"}, {"offsetInBeginSection": 111, "offsetInEndSection": 185, "text": "One purpose is to provide a molecular anatomy of craniofacial development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040"}, {"offsetInBeginSection": 1241, "offsetInEndSection": 1336, "text": "This FACEBASE resource is designed to promote discovery by the craniofacial research community.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040"}]}, {"id": "5a79d25dfaa1ab7d2e00000f", "body": "Does wheat belongs to the genus Avena, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24226111", "http://www.ncbi.nlm.nih.gov/pubmed/8984007", "http://www.ncbi.nlm.nih.gov/pubmed/12669804", "http://www.ncbi.nlm.nih.gov/pubmed/25120168", "http://www.ncbi.nlm.nih.gov/pubmed/10464792", "http://www.ncbi.nlm.nih.gov/pubmed/29083384"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "The genus Avena consists of at least 23 species composed of three ploidy levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 728, "offsetInEndSection": 812, "text": "We have also done similar analysis of the Avena genus using a rDNA clone from wheat.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1103, "text": "These molecular probes can be useful in studying the genomic relationships of Avena and can provide some clues as to the origin of the cultivated Avena species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Chromosomal and genomic organization of Ty1-copia-like retrotransposon sequences in the genus Avena.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1451, "text": "However, under high stringency conditions, it hybridized only on Arrhenatherum DNA, which is considered to be the genus most closely related to Avena.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Isolation and identification of Triticeae chromosome 1 receptor-like kinase genes (Lrk10) from diploid, tetraploid, and hexaploid species of the genus Avena.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804"}, {"offsetInBeginSection": 378, "offsetInEndSection": 588, "text": "Cluster (phylogenetic) analyses showed that all of the oat DNA sequences amplified with these primers are orthologous to the wheat and barley sequences that are located on chromosome 1 of the Triticeae species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804"}, {"offsetInBeginSection": 1332, "offsetInEndSection": 1486, "text": "The present results identify a novel protein family affecting cereal kernel texture and would further elucidate the phylogenetic evolution of Avena genus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1240, "text": "Further, the chromosomes involved in three C-A and three C-D intergenomic translocations in Avena murphyi (AC genomes) and Avena sativa cv.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1528, "text": "Based on its physical distribution and Southern hybridization patterns, a parental retrotransposon represented by pAs17 appears to have been active at least once during the evolution of the A genome in species of the Avena genus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792"}]}, {"id": "5a68fd01b750ff445500001b", "body": "What is included in the fourth generation HIV test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23984592", "http://www.ncbi.nlm.nih.gov/pubmed/29062724", "http://www.ncbi.nlm.nih.gov/pubmed/28846743", "http://www.ncbi.nlm.nih.gov/pubmed/24342480", "http://www.ncbi.nlm.nih.gov/pubmed/24342477", "http://www.ncbi.nlm.nih.gov/pubmed/16908076", "http://www.ncbi.nlm.nih.gov/pubmed/19320855", "http://www.ncbi.nlm.nih.gov/pubmed/28710996", "http://www.ncbi.nlm.nih.gov/pubmed/25464967", "http://www.ncbi.nlm.nih.gov/pubmed/11595590"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "[Evaluation of an immunochromatographic fourth generation test for the rapid diagnosis of acute HIV infection].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The early diagnosis of human immunodeficiency virus (HIV) infection is important to provide effective antiviral treatment and to prevent transmission of HIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 158, "offsetInEndSection": 371, "text": "One of the key issues to achieve this goal is to shorten the so-called \"diagnostic window period\" when the humoral immune response toward the virus is not fully developed during the acute phase of HIV-1 infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 372, "offsetInEndSection": 611, "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 612, "offsetInEndSection": 720, "text": "E4G is the first and only fourth generation immunochromatographic HIV test kit approved in Japan at present.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 721, "offsetInEndSection": 949, "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1125, "text": "E4G detected HIV infection in 18/25 specimens (sensitivity : 72.0%), of which the viral Ag was detected in only 2 specimens (8.0%) bearing a viral load > 10 million copies/mL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1198, "text": "No spesimens were simultaneously reactive to both Ag and Ab against HIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1432, "text": "In contrast the fourth generation Ag/ Ab ELISA scored all the 25 AHI specimens positive (sensitivity : 100%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1617, "text": "Overall, although having the merit of offering a rapid diagnostic test for HIV infection, E4G does not provide a sensitivity in AHI diagnosis superior to test kits currently available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}]}, {"id": "5a6d2558b750ff4455000036", "body": "Does Uc.160 promote cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28382457"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Expression and function of Uc.160+, a transcribed ultraconserved region, in gastric cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 245, "offsetInEndSection": 399, "text": "We previously discovered the downregulation of T-UCR expression in gastric cancer (GC), indicating that T-UCRs could play an important role in GC biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 400, "offsetInEndSection": 491, "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1263, "text": "Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1492, "text": "We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1492, "offsetInEndSection": 1592, "text": "CONCLUSIONS: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1361, "text": "The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 824, "offsetInEndSection": 948, "text": "We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 169, "offsetInEndSection": 244, "text": "It has been reported that T-UCRs have distinct signatures in human cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 948, "offsetInEndSection": 1139, "text": "RESULTS: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}]}, {"id": "5a8712af61bb38fb24000002", "body": "What is the link between psoriatic arthritis and depression", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21794775", "http://www.ncbi.nlm.nih.gov/pubmed/27258525", "http://www.ncbi.nlm.nih.gov/pubmed/27221798", "http://www.ncbi.nlm.nih.gov/pubmed/28507445", "http://www.ncbi.nlm.nih.gov/pubmed/19151962", "http://www.ncbi.nlm.nih.gov/pubmed/24407907", "http://www.ncbi.nlm.nih.gov/pubmed/23908539", "http://www.ncbi.nlm.nih.gov/pubmed/22015150", "http://www.ncbi.nlm.nih.gov/pubmed/28733473", "http://www.ncbi.nlm.nih.gov/pubmed/28320454"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "[Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 28, "offsetInEndSection": 112, "text": "OBJECTIVE: Psychological impairment is frequent in patients with rheumatic diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 113, "offsetInEndSection": 281, "text": "The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 359, "offsetInEndSection": 556, "text": "Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 557, "offsetInEndSection": 707, "text": "Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score \u226511 or those receiving pharmacological treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 708, "offsetInEndSection": 820, "text": "A logistics regression model was used to know which variables were related to symptoms of anxiety or depression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1106, "text": "Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 1106, "offsetInEndSection": 1275, "text": "CONCLUSION: The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Psoriasis patients with moderate to severe disease often present with depression and insomnia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525"}]}, {"id": "5a6900ebb750ff445500001d", "body": "Which disease is diagnosed using the Finkelstein's test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15680568", "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "http://www.ncbi.nlm.nih.gov/pubmed/12723309", "http://www.ncbi.nlm.nih.gov/pubmed/26538761", "http://www.ncbi.nlm.nih.gov/pubmed/15792200", "http://www.ncbi.nlm.nih.gov/pubmed/1402284", "http://www.ncbi.nlm.nih.gov/pubmed/10070674"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Finkelstein's test: a biomechanical analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "PURPOSE: Finkelstein's test is the classic diagnostic test for de Quervain's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 86, "offsetInEndSection": 333, "text": "Finkelstein hypothesized that the entry of the muscle bellies of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons into the first extensor compartment was responsible for the findings observed in his now eponymous test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 334, "offsetInEndSection": 559, "text": "We agree with Finkelstein's hypothesis and further hypothesize that this position would induce measurable bulk (muscle mass within the retinaculum) and tethering (stretching of synovial tissue) effects within the compartment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 746, "offsetInEndSection": 905, "text": "Gliding resistance and excursion were measured in 4 different wrist positions, including the wrist position of Finkelstein's test (30 degrees ulnar deviation).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1542, "offsetInEndSection": 1746, "text": "CONCLUSIONS: We showed that in the position of Finkelstein's test the EPB tendon is significantly more distal and has significantly greater bulk and tethering effect compared with the other EPB positions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1747, "offsetInEndSection": 1825, "text": "This is not the case for the APL tendon in the position of Finkelstein's test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1826, "offsetInEndSection": 1942, "text": "These results suggest that an abnormal Finkelstein's test reflects differences of the EPB more than it does the APL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The wrist hyperflexion and abduction of the thumb (WHAT) test: a more specific and sensitive test to diagnose de Quervain tenosynovitis than the Eichhoff's Test.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "De Quervain's disease has different clinical features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762"}]}, {"id": "5a6e1280b750ff4455000037", "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28941722"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Upregulation of uc.189 in patients with esophageal squamous cell carcinoma and its clinicopathologic value.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Ultraconserved elements (UCEs) encoding noncoding RNAs serve as important regulators in cancer biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 104, "offsetInEndSection": 255, "text": "Until now, the role of the UCE uc.189 in human cancers remains undefined and the clinical significance of uc.189 in esophageal cancers remains unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 256, "offsetInEndSection": 371, "text": "This study was to identify the prognostic value of uc.189 expression in esophageal squamous cell carcinomas (ESCC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 372, "offsetInEndSection": 572, "text": "Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression level of uc.189 in matched cancerous tissues and adjacent noncancerous tissues from 152 patients with ESCC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 573, "offsetInEndSection": 666, "text": "The correlation of uc.189 with clinicopathological features and prognosis were also analyzed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 667, "offsetInEndSection": 797, "text": "The expression of uc.189 was significantly higher in human ESCC compared with the adjacent noncancerous tissues (122/152, 80.3%, p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}]}, {"id": "5a87140a61bb38fb24000003", "body": "What is Chronic Wasting Disease (CWD) in deer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27575545", "http://www.ncbi.nlm.nih.gov/pubmed/17553219", "http://www.ncbi.nlm.nih.gov/pubmed/12680636", "http://www.ncbi.nlm.nih.gov/pubmed/16439622", "http://www.ncbi.nlm.nih.gov/pubmed/27711208", "http://www.ncbi.nlm.nih.gov/pubmed/17020952", "http://www.ncbi.nlm.nih.gov/pubmed/18387626", "http://www.ncbi.nlm.nih.gov/pubmed/28193766", "http://www.ncbi.nlm.nih.gov/pubmed/17092889", "http://www.ncbi.nlm.nih.gov/pubmed/15542685"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Chronic Wasting Disease Drives Population Decline of White-Tailed Deer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 142, "offsetInEndSection": 317, "text": "Despite a 100% fatality rate, areas of high prevalence, and increasingly expanding geographic endemic areas, little is known about the population-level effects of CWD in deer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 318, "offsetInEndSection": 473, "text": "To investigate these effects, we tested the null hypothesis that high prevalence CWD did not negatively impact white-tailed deer population sustainability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 474, "offsetInEndSection": 684, "text": "The specific objectives of the study were to monitor CWD-positive and CWD-negative white-tailed deer in a high-prevalence CWD area longitudinally via radio-telemetry and global positioning system (GPS) collars.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 840, "offsetInEndSection": 1059, "text": "The CWD prevalence was higher in females (42%) than males (28.8%) and hunter harvest and clinical CWD were the most frequent causes of mortality, with CWD-positive deer over-represented in harvest and total mortalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1278, "text": "Survival was significantly lower for CWD-positive deer and separately by sex; CWD-positive deer were 4.5 times more likely to die annually than CWD-negative deer while bucks were 1.7 times more likely to die than does.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 1357, "offsetInEndSection": 1629, "text": "We show that a chronic disease that becomes endemic in wildlife populations has the potential to be population-limiting and the strong population-level effects of CWD suggest affected populations are not sustainable at high disease prevalence under current harvest levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Levels of abnormal prion protein in deer and elk with chronic wasting disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219"}]}, {"id": "5a69031bb750ff445500001e", "body": "Can doxycycline cause photosensitivity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9214073", "http://www.ncbi.nlm.nih.gov/pubmed/17160610", "http://www.ncbi.nlm.nih.gov/pubmed/26299894", "http://www.ncbi.nlm.nih.gov/pubmed/10233667", "http://www.ncbi.nlm.nih.gov/pubmed/21879777", "http://www.ncbi.nlm.nih.gov/pubmed/23182067", "http://www.ncbi.nlm.nih.gov/pubmed/17315050", "http://www.ncbi.nlm.nih.gov/pubmed/3684731", "http://www.ncbi.nlm.nih.gov/pubmed/15262663", "http://www.ncbi.nlm.nih.gov/pubmed/26189561"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "A case of phototoxic onycholysis secondary to treatment with doxycycline is presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9214073"}, {"offsetInBeginSection": 1908, "offsetInEndSection": 2075, "text": "Treatment with doxycycline is cheap and relatively safe, but gastrointestinal symptoms and photosensitivity reactions can be expected more often than with ceftriaxone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "OBJECTIVES: Many patients undergoing long-term doxycycline treatment do not regularly take their treatment because of photosensitivity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299894"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Is monochromatic irradiation testing useful in the differentiation of drug-induced photosensitivity from chronic actinic dermatitis?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10233667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Management of nonsexually acquired genital ulceration using oral and topical corticosteroids followed by doxycycline prophylaxis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1212, "text": "Eight (89%) had a history of recurrent ulcers and 6 (66%) commenced doxycycline prophylaxis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067"}, {"offsetInBeginSection": 1384, "offsetInEndSection": 1472, "text": "One patient experienced mild photosensitivity from doxycycline but continued to take it.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Update on rosacea and anti-inflammatory-dose doxycycline.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050"}, {"offsetInBeginSection": 614, "offsetInEndSection": 786, "text": "Oracea is a 40 mg capsule of doxycycline monohydrate, containing 30 mg immediate-release and 10 mg delayed-release doxycycline beads (\"anti-inflammatory-dose doxycycline\").", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1632, "text": "Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050"}]}, {"id": "5a6e21b4b750ff445500003a", "body": "Are paralog genes co-regulated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18493055", "http://www.ncbi.nlm.nih.gov/pubmed/27634932", "http://www.ncbi.nlm.nih.gov/pubmed/20621981", "http://www.ncbi.nlm.nih.gov/pubmed/20660482"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Analysis of the Drosophila melanogaster testes transcriptome reveals coordinate regulation of paralogous genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Gene duplications have been broadly implicated in the generation of testis-specific genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 414, "offsetInEndSection": 510, "text": "Among the detected 69 genes downregulated in testes, a large fraction is required for viability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 511, "offsetInEndSection": 839, "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 840, "offsetInEndSection": 940, "text": "The numbers of identified co-regulated and anti-regulated pairs were higher than expected by chance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1489, "text": "Further, interspecific changes in testis bias of expression are generally correlated within the co-regulated pairs and are anti-correlated within the anti-regulated pairs, suggesting coordinated regulation within both types of paralogous gene pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Co-regulation of paralog genes in the three-dimensional chromatin architecture.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 164, "offsetInEndSection": 278, "text": "Consequently, paralogs show correlation in gene expression whereby the mechanisms of co-regulation remain unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 279, "offsetInEndSection": 399, "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}]}, {"id": "5a87145861bb38fb24000004", "body": "What causes Black Lung?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2933965", "http://www.ncbi.nlm.nih.gov/pubmed/17300721", "http://www.ncbi.nlm.nih.gov/pubmed/16304297", "http://www.ncbi.nlm.nih.gov/pubmed/28450031", "http://www.ncbi.nlm.nih.gov/pubmed/2806196", "http://www.ncbi.nlm.nih.gov/pubmed/17516558", "http://www.ncbi.nlm.nih.gov/pubmed/16497850", "http://www.ncbi.nlm.nih.gov/pubmed/26437452", "http://www.ncbi.nlm.nih.gov/pubmed/7810543", "http://www.ncbi.nlm.nih.gov/pubmed/11170158"], "snippets": [{"offsetInBeginSection": 206, "offsetInEndSection": 278, "text": "This problem is discussed in relation to the federal black lung program.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2933965"}, {"offsetInBeginSection": 279, "offsetInEndSection": 519, "text": "Conflicting definitions of terms--coal workers' pneumoconiosis as defined by the medical profession, pneumoconiosis as defined by the United States Congress, and the popular term, black lung--are important considerations in this discussion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2933965"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Black tea prevents cigarette smoke-induced apoptosis and lung damage.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "BACKGROUND: Cigarette smoking is a major cause of lung damage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 136, "offsetInEndSection": 191, "text": "Oxidative stress may lead to apoptosis and lung injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 192, "offsetInEndSection": 374, "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1068, "offsetInEndSection": 1143, "text": "RESULTS: Cigarette smoke exposure to a guinea pig model caused lung damage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1144, "offsetInEndSection": 1263, "text": "It appeared that oxidative stress was the initial event, which was followed by inflammation, apoptosis and lung injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1420, "offsetInEndSection": 1595, "text": "CONCLUSION: Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Evaluation of the causes for racial disparity in surgical treatment of early stage lung cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304297"}]}, {"id": "5a6f7e6ab750ff4455000052", "body": "List four principles of medical ethics.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11794075", "http://www.ncbi.nlm.nih.gov/pubmed/14519842", "http://www.ncbi.nlm.nih.gov/pubmed/7463428", "http://www.ncbi.nlm.nih.gov/pubmed/26793677", "http://www.ncbi.nlm.nih.gov/pubmed/23975951", "http://www.ncbi.nlm.nih.gov/pubmed/15183570", "http://www.ncbi.nlm.nih.gov/pubmed/21625670", "http://www.ncbi.nlm.nih.gov/pubmed/25516952", "http://www.ncbi.nlm.nih.gov/pubmed/16731739"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Teaching medical ethics in Basra: perspective of students and graduates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The University of Basra Medical College introduced a course on medical ethics for undergraduate students in 1994.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 114, "offsetInEndSection": 299, "text": "We explored the opinions of 54 graduates and 52 final-year medical students about the benefits they perceive they gained from the course and its relevance to their training or practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 404, "offsetInEndSection": 538, "text": "Over 80% of graduates and students thought the course was either very relevant or relevant to some extent to the practice of medicine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 684, "offsetInEndSection": 809, "text": "Confidentiality, physician liability and ethical issues concerning recent medical innovations were listed by few respondents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 810, "offsetInEndSection": 928, "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Ethics needs principles--four can encompass the rest--and respect for autonomy should be \"first among equals\".", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "A philosophy of a clinically based medical ethics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Pellegrino and Siegler have argued that medical ethics must be taught 'at the bedside', or clinically.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}]}, {"id": "5a6e22b9b750ff445500003b", "body": "What is CellMaps?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27296979"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Web-based network analysis and visualization using CellMaps.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 421, "offsetInEndSection": 637, "text": "IMPLEMENTATION: The application is available at: http://cellmaps.babelomics.org/ and the code can be found in: https://github.com/opencb/cell-maps The client is implemented in JavaScript and the server in C and Java.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 637, "offsetInEndSection": 674, "text": "CONTACT: jdopazo@cipf.esSUPPLEMENTARY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "UNLABELLED: : CellMaps is an HTML5 open-source web tool that allows displaying, editing, exploring and analyzing biological networks as well as integrating metadata into them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 317, "offsetInEndSection": 420, "text": "CellMaps can easily be integrated in any web page by using an available JavaScript API.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 675, "offsetInEndSection": 746, "text": "INFORMATION: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}, {"offsetInBeginSection": 176, "offsetInEndSection": 316, "text": "Computations and analyses are remotely executed in high-end servers, and all the functionalities are available through RESTful web services.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979"}]}, {"id": "5a8714e261bb38fb24000005", "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2408761", "http://www.ncbi.nlm.nih.gov/pubmed/9933592", "http://www.ncbi.nlm.nih.gov/pubmed/3037325", "http://www.ncbi.nlm.nih.gov/pubmed/16467265", "http://www.ncbi.nlm.nih.gov/pubmed/3019671", "http://www.ncbi.nlm.nih.gov/pubmed/2160581", "http://www.ncbi.nlm.nih.gov/pubmed/9242905", "http://www.ncbi.nlm.nih.gov/pubmed/11557765", "http://www.ncbi.nlm.nih.gov/pubmed/12270133", "http://www.ncbi.nlm.nih.gov/pubmed/9223284"], "snippets": [{"offsetInBeginSection": 368, "offsetInEndSection": 434, "text": "Additional adenosine residues are added during further incubation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1041, "text": "Like the in vitro splicing reaction, the in vitro polyadenylation reaction is inhibited by adding antiserum against the small nuclear ribonucleoprotein particle containing U1 RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 818, "offsetInEndSection": 939, "text": "As few as 5 adenosine residues were sufficient to achieve this stimulation, and generic sequences were equally effective.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1151, "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Formation of mRNA 3' termini involves cleavage of an mRNA precursor and polyadenylation of the newly formed end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}, {"offsetInBeginSection": 267, "offsetInEndSection": 392, "text": "The 5' half-molecule contained sequences upstream but not downstream of the poly(A) site and ended in a 3'-terminal hydroxyl.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}, {"offsetInBeginSection": 614, "offsetInEndSection": 728, "text": "The 3' terminus of the 5' half-molecule was the adenosine 10 nucleotides downstream of AAUAAA, at the +1 position.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1133, "text": "5' half-molecules generated in the presence of EDTA (which blocks polyadenylation, but not cleavage) ended at the adenosine at position +1 of the precursor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1403, "text": "5' half-molecules formed in 3'-dATP-containing reactions contained a single 3'-deoxyadenosine (cordycepin) residue added onto the +1 adenosine and were poor polyadenylation substrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1574, "text": "We infer that the +1 adenosine of the precursor becomes the first A of the poly(A) tract and provides a 3' hydroxyl group to which poly(A) is added posttranscriptionally.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}]}, {"id": "5a6f829eb750ff4455000054", "body": "Can multiple myeloma patients develop hyperviscosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7699907", "http://www.ncbi.nlm.nih.gov/pubmed/2385441", "http://www.ncbi.nlm.nih.gov/pubmed/22827791", "http://www.ncbi.nlm.nih.gov/pubmed/9046114", "http://www.ncbi.nlm.nih.gov/pubmed/26623375", "http://www.ncbi.nlm.nih.gov/pubmed/694674", "http://www.ncbi.nlm.nih.gov/pubmed/14631546", "http://www.ncbi.nlm.nih.gov/pubmed/5415687", "http://www.ncbi.nlm.nih.gov/pubmed/1201229", "http://www.ncbi.nlm.nih.gov/pubmed/17315105"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 26, "text": "[Hyperviscosity syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Common clinical manifestations of the hyperviscosity syndrome are bleeding from mucosal membrane, retinopathy, visual disturbance and neurological disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 246, "offsetInEndSection": 421, "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 520, "offsetInEndSection": 744, "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "IgA myeloma complicated by fractures of the bones and hyperviscosity syndrome--report of an autopsied case.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "A case of IgA (kappa type) myeloma complicated by fractures of the bones and hyperviscosity syndrome is presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 115, "offsetInEndSection": 244, "text": "A 56-year-old woman who had been followed as an outpatient with diabetes mellitus for about 16 years, developed multiple myeloma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 245, "offsetInEndSection": 456, "text": "She also showed symptoms and signs of hyperviscosity syndrome; hemorrhagic diathesis, blurred vision and episodes of transient ischemic attacks of the brain, and fractures of the bones by small powers of trauma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 457, "offsetInEndSection": 614, "text": "At autopsy, almost all bones showed infiltration of multiple myeloma of IgA-kappa type and severe osteoporosis accompanied with proliferation of osteoclasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 615, "offsetInEndSection": 713, "text": "The association of IgA myeloma with hyperviscosity syndrome and/or bone destruction was discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}]}, {"id": "5a6e2578b750ff445500003d", "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22847932", "http://www.ncbi.nlm.nih.gov/pubmed/29028898", "http://www.ncbi.nlm.nih.gov/pubmed/27008016", "http://www.ncbi.nlm.nih.gov/pubmed/24227674", "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "http://www.ncbi.nlm.nih.gov/pubmed/27347386", "http://www.ncbi.nlm.nih.gov/pubmed/26834993", "http://www.ncbi.nlm.nih.gov/pubmed/26578583", "http://www.ncbi.nlm.nih.gov/pubmed/29052185", "http://www.ncbi.nlm.nih.gov/pubmed/26819470"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "easyRNASeq: a bioconductor package for processing RNA-Seq data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "MOTIVATION: RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 169, "offsetInEndSection": 270, "text": "Numerous 'Bioconductor' packages are available for next-generation sequencing data loading in R, e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 378, "offsetInEndSection": 496, "text": "However, the processing tasks lying in between these require the precise interplay of many Bioconductor packages, e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 556, "offsetInEndSection": 744, "text": "RESULTS: We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 744, "offsetInEndSection": 873, "text": "AVAILABILITY: The package is implemented in R (as of version 2.15) and is available from Bioconductor (as of version 2.10) at the", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1002, "text": "URL: http://bioconductor.org/packages/release/bioc/html/easyRNASeq.html, where installation and usage instructions can be found.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898"}, {"offsetInBeginSection": 289, "offsetInEndSection": 540, "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Quantitative Comparison of Large-Scale DNA Enrichment Sequencing Data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016"}]}, {"id": "5a8715a961bb38fb24000006", "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28683325"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Metabotropic glutamate receptor 5 (mGluR5) has been implicated in Alzheimer's disease (AD) pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}, {"offsetInBeginSection": 102, "offsetInEndSection": 183, "text": "We sought to understand whether mGluR5's role in AD requires glutamate signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}, {"offsetInBeginSection": 184, "offsetInEndSection": 393, "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}, {"offsetInBeginSection": 394, "offsetInEndSection": 531, "text": "Binding of the SAM to mGluR5 does not change glutamate signaling but strongly reduces mGluR5 interaction with cellular prion protein (PrP", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}]}, {"id": "5a6f853ab750ff4455000055", "body": "Which disease can be diagnosed with the \"probe to bone\" test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7853630", "http://www.ncbi.nlm.nih.gov/pubmed/27369321", "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "http://www.ncbi.nlm.nih.gov/pubmed/17259493", "http://www.ncbi.nlm.nih.gov/pubmed/7770390", "http://www.ncbi.nlm.nih.gov/pubmed/24356116", "http://www.ncbi.nlm.nih.gov/pubmed/18601422", "http://www.ncbi.nlm.nih.gov/pubmed/19141236", "http://www.ncbi.nlm.nih.gov/pubmed/1922909", "http://www.ncbi.nlm.nih.gov/pubmed/19485522"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Probing to bone in infected pedal ulcers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 70, "offsetInEndSection": 202, "text": "DESIGN: We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 203, "offsetInEndSection": 363, "text": "We then examined the relationship between detection of bone and the presence or absence of osteomyelitis that was defined histopathologically and/or clinically.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 595, "offsetInEndSection": 764, "text": "Bone was detected by probing in 33 of 50 ulcers with contiguous osteomyelitis; in contrast, bone was probed in only four of 26 ulcers without contiguous osteomyelitis (P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 765, "offsetInEndSection": 930, "text": "CONCLUSIONS: Palpation of bone in the depths of infected pedal ulcers in patients with diabetes is strongly correlated with the presence of underlying osteomyelitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1057, "text": "If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are unnecessary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 1058, "offsetInEndSection": 1172, "text": "Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}, {"offsetInBeginSection": 280, "offsetInEndSection": 433, "text": "We searched Ovid Medline and Scopus databases for studies using the keywords \"probe to bone,\" \"osteomyelitis,\" and \"diabetic foot\" from 1946 to May 2015.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}]}, {"id": "5a6e33e4b750ff4455000041", "body": "Describe annotatr", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28369316"], "snippets": [{"offsetInBeginSection": 1267, "offsetInEndSection": 1576, "text": "Overall, annotatr enables a richer biological interpretation of experiments.Availability and Implementation: http://bioconductor.org/packages/annotatr/ and https://github.com/rcavalcante/annotatr.Contact: rcavalca@umich.edu.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1266, "text": "We demonstrate that annotatr is up to 27\u00d7 faster than comparable R packages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 775, "offsetInEndSection": 918, "text": "The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "annotatr: genomic regions in context.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 100, "offsetInEndSection": 263, "text": "These may include differentially methylated CpGs/regions, transcription factor binding sites, interacting chromatin regions, or GWAS-associated SNPs, among others.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 383, "offsetInEndSection": 774, "text": "Existing tools are limited by a lack of annotation sources and flexible options, the time it takes to annotate regions, an artificial one-to-one region-to-annotation mapping, a lack of visualization options to easily summarize data, or some combination thereof.Results: We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 264, "offsetInEndSection": 382, "text": "A common analysis step is to annotate such genomic regions to genomic annotations (promoters, exons, enhancers, etc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Motivation: Analysis of next-generation sequencing data often results in a list of genomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1189, "text": "A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316"}]}, {"id": "5a8718c861bb38fb24000008", "body": "What are check point inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27528363", "http://www.ncbi.nlm.nih.gov/pubmed/26775673", "http://www.ncbi.nlm.nih.gov/pubmed/28878676", "http://www.ncbi.nlm.nih.gov/pubmed/28865357", "http://www.ncbi.nlm.nih.gov/pubmed/27403706"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 488, "offsetInEndSection": 570, "text": "OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 570, "offsetInEndSection": 769, "text": "METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 835, "offsetInEndSection": 972, "text": "RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1071, "text": "CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "BACKGROUND: We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 539, "offsetInEndSection": 766, "text": "CONCLUSION: Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 236, "offsetInEndSection": 423, "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676"}, {"offsetInBeginSection": 588, "offsetInEndSection": 715, "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676"}]}, {"id": "5a6f87c5b750ff4455000056", "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27336863", "http://www.ncbi.nlm.nih.gov/pubmed/17562045", "http://www.ncbi.nlm.nih.gov/pubmed/16462517", "http://www.ncbi.nlm.nih.gov/pubmed/25368273", "http://www.ncbi.nlm.nih.gov/pubmed/2110929", "http://www.ncbi.nlm.nih.gov/pubmed/24159176", "http://www.ncbi.nlm.nih.gov/pubmed/20084442", "http://www.ncbi.nlm.nih.gov/pubmed/12064854", "http://www.ncbi.nlm.nih.gov/pubmed/24153350", "http://www.ncbi.nlm.nih.gov/pubmed/1608349"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Family history of lymphoma and risk for solid tumors in patients with Sjogren's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "It has been recognized that primary Sjogren's syndrome predisposes to the development of lymphoproliferative disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 120, "offsetInEndSection": 217, "text": "However, it is so far uncertain whether these patients are at an increased risk for solid tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 218, "offsetInEndSection": 383, "text": "Herein we report two cases of primary Sjogren's syndrome complicated by breast and lung cancer and who have a strong family history for lymphoproliferative diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 117, "offsetInEndSection": 205, "text": "Reports have appeared suggesting increased cancer risk in autoimmune rheumatic diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517"}, {"offsetInBeginSection": 206, "offsetInEndSection": 356, "text": "Evidence has been accumulating recently in rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma/systemic sclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517"}, {"offsetInBeginSection": 452, "offsetInEndSection": 637, "text": "FINDINGS: Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517"}, {"offsetInBeginSection": 638, "offsetInEndSection": 738, "text": "There are data suggesting an increased risk for rheumatoid arthritis patients regarding lung cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517"}]}, {"id": "5a6e3d21b750ff4455000043", "body": "What is BBCAnalyzer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28241736"], "snippets": [{"offsetInBeginSection": 2023, "offsetInEndSection": 2100, "text": "Video demonstrating the exemplary usage of the web application \"BBCAnalyzer\".", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 969, "offsetInEndSection": 1058, "text": "In addition to an ordinary textual report, BBCAnalyzer reports highly customizable plots.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 666, "offsetInEndSection": 809, "text": "BBCAnalyzer is able to visualize base counts at predefined positions or regions in any sequence alignment data that are available as BAM files.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1225, "text": "Information on the counted number of bases, the reference bases, known mutations or polymorphisms, called mutations and base qualities is summarized in a single plot.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 1544, "offsetInEndSection": 1606, "text": "The R package is freely available at http://bioconductor.org .", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 499, "offsetInEndSection": 665, "text": "RESULTS: BBCAnalyzer (Bases By CIGAR Analyzer) provides a novel visual approach to facilitate this step of time-consuming, manual inspection of common mutation sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 1990, "offsetInEndSection": 2022, "text": "Additional file 3: Supplement_3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "BACKGROUND: Deriving valid variant calling results from raw next-generation sequencing data is a particularly challenging task, especially with respect to clinical diagnostics and personalized medicine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 1607, "offsetInEndSection": 1667, "text": "The local web application is available at Additional file 2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}, {"offsetInBeginSection": 1408, "offsetInEndSection": 1543, "text": "CONCLUSIONS: BBCAnalyzer provides a unique, novel approach to facilitate variant calling where classical tools frequently fail to call.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736"}]}, {"id": "5a871a6861bb38fb24000009", "body": "What disease is the ALK tyrosine kinase associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27573755", "http://www.ncbi.nlm.nih.gov/pubmed/20223922", "http://www.ncbi.nlm.nih.gov/pubmed/25407901", "http://www.ncbi.nlm.nih.gov/pubmed/25351247", "http://www.ncbi.nlm.nih.gov/pubmed/18923525", "http://www.ncbi.nlm.nih.gov/pubmed/21829174", "http://www.ncbi.nlm.nih.gov/pubmed/27217763", "http://www.ncbi.nlm.nih.gov/pubmed/23714228", "http://www.ncbi.nlm.nih.gov/pubmed/23154552", "http://www.ncbi.nlm.nih.gov/pubmed/26811689"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "The role of the ALK receptor in cancer biology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "A vast array of oncogenic variants has been identified for anaplastic lymphoma kinase (ALK).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 218, "offsetInEndSection": 393, "text": "This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of patients with cancer that is ALK-positive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 394, "offsetInEndSection": 536, "text": "A variety of ALK gene alterations have been described across a range of tumour types, including point mutations, deletions and rearrangements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 537, "offsetInEndSection": 817, "text": "A wide variety of ALK fusions, in which the kinase domain of ALK and the amino-terminal portion of various protein partners are fused, occur in cancer, with echinoderm microtubule-associated protein-like 4 (EML4)-ALK being the most prevalent in non-small-cell lung cancer (NSCLC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1273, "text": "Two ALK tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, are currently approved in Europe for use in ALK-positive NSCLC and several others are in development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1465, "text": "These ALK TKIs bind slightly differently within the ATP-binding pocket of the ALK kinase domain and are associated with the emergence of different resistance mutation patterns during therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1466, "offsetInEndSection": 1573, "text": "This emphasises the need to tailor the sequence of ALK TKIs according to the ALK signature of each patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1574, "offsetInEndSection": 1739, "text": "Research into the oncogenic functions of ALK, and fast paced development of ALK inhibitors, has substantially improved outcomes for patients with ALK-positive NSCLC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1740, "offsetInEndSection": 1875, "text": "Limited data are available surrounding the physiological ligand-stimulated activation of ALK signalling and further research is needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}]}, {"id": "5a6f8dc6b750ff4455000058", "body": "Is trastuzumab associated cardiotoxicity reversible?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26836985", "http://www.ncbi.nlm.nih.gov/pubmed/19669637", "http://www.ncbi.nlm.nih.gov/pubmed/24905295", "http://www.ncbi.nlm.nih.gov/pubmed/18514938", "http://www.ncbi.nlm.nih.gov/pubmed/21310845", "http://www.ncbi.nlm.nih.gov/pubmed/15177418", "http://www.ncbi.nlm.nih.gov/pubmed/18484781", "http://www.ncbi.nlm.nih.gov/pubmed/23282614", "http://www.ncbi.nlm.nih.gov/pubmed/14613026", "http://www.ncbi.nlm.nih.gov/pubmed/19147689"], "snippets": [{"offsetInBeginSection": 158, "offsetInEndSection": 252, "text": "As a paradox in cancer survivors, delayed cardiotoxicity has emerged as a significant problem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 253, "offsetInEndSection": 562, "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 563, "offsetInEndSection": 837, "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 1156, "offsetInEndSection": 1306, "text": "On the other hand, early detection and prompt therapy of anthracycline associated cardiotoxicity can lead to substantial recovery of cardiac function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "INTRODUCTION: Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 286, "offsetInEndSection": 438, "text": "METHODS: This paper reviews the cardiotoxicity, associated with trastuzumab use and discusses the risk assessment and management of cardiac dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 438, "offsetInEndSection": 599, "text": "RESULTS: The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 600, "offsetInEndSection": 778, "text": "Type II cardiac changes occur in trastuzumab-treated patients, which do not appear to be dose-related, are not associated with histological changes, and are generally reversible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 779, "offsetInEndSection": 1015, "text": "Several risk factors for cardiac events have been identified and assessing levels of troponin I and N-terminal pro-brain B-type natriuretic peptide before and after treatment with trastuzumab may allow early detection of cardiotoxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}]}, {"id": "5a6e3fe3b750ff4455000044", "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29078818"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 274, "offsetInEndSection": 403, "text": "However, the underlying mechanisms remain poorly understood and it is unknown how the sequences of lncRNA dictate their function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 403, "offsetInEndSection": 500, "text": "RESULTS: Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 501, "offsetInEndSection": 658, "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 659, "offsetInEndSection": 779, "text": "A cross-species analysis identifies a highly conserved sequence element in LINC-PINT that is essential for its function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 780, "offsetInEndSection": 966, "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1206, "text": "CONCLUSIONS: Our findings support a conserved functional co-dependence between LINC-PINT and PRC2 and lead us to propose a new mechanism where the lncRNA regulates the availability of free PRC2 at the proximity of co-regulated genomic loci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "BACKGROUND: It is now obvious that the majority of cellular transcripts do not code for proteins, and a significant subset of them are long non-coding RNAs (lncRNAs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 167, "offsetInEndSection": 273, "text": "Many lncRNAs show aberrant expression in cancer, and some of them have been linked to cell transformation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}]}, {"id": "5a871b8d61bb38fb2400000a", "body": "What body process does the Dentate Gyrus Mossy Cell control?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18189312", "http://www.ncbi.nlm.nih.gov/pubmed/9187278", "http://www.ncbi.nlm.nih.gov/pubmed/17765742", "http://www.ncbi.nlm.nih.gov/pubmed/14999076", "http://www.ncbi.nlm.nih.gov/pubmed/10531454", "http://www.ncbi.nlm.nih.gov/pubmed/1308178", "http://www.ncbi.nlm.nih.gov/pubmed/18077687", "http://www.ncbi.nlm.nih.gov/pubmed/24811867", "http://www.ncbi.nlm.nih.gov/pubmed/7721998", "http://www.ncbi.nlm.nih.gov/pubmed/11043552"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Calretinin expression in hilar mossy cells of the hippocampal dentate gyrus of nonhuman primates and humans.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Mossy cells, the major excitatory neurons of the hilus of the dentate gyrus constitutively express calretinin in several rodent species, including mouse and hamster, but not in rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 183, "offsetInEndSection": 385, "text": "Several studies suggest that mossy cells of the monkey dentate gyrus are calretinin-positive, but others have reported mossy cells in monkeys to be devoid of detectable calretinin-like immunoreactivity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 386, "offsetInEndSection": 579, "text": "In the present study, the hilar region was investigated throughout the entire longitudinal extent of the hippocampal dentate gyrus in both Old World and New World monkeys, as well as in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 580, "offsetInEndSection": 774, "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 775, "offsetInEndSection": 1099, "text": "The associational pathway, formed by axons of mossy cells in the inner dentate molecular layer was calretinin-positive in more caudal sections, suggesting that mossy cell axon terminals may contain calretinin, whereas mossy cell somata may contain calretinin in a concentration too low to be detected by immunocytochemistry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1228, "text": "In contrast, human mossy cells appear to be devoid of calretinin immunoreactivity in both their somata and their axon terminals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Septal innervation of mossy cells in the hilus of the rat dentate gyrus: an anterograde tracing and intracellular labeling study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}, {"offsetInBeginSection": 137, "offsetInEndSection": 279, "text": "They project along the septotemporal axis of the dentate gyrus and may thus influence the hippocampal signal flow in a longitudinal direction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}]}, {"id": "5a6f922fb750ff4455000059", "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27375734", "http://www.ncbi.nlm.nih.gov/pubmed/28090050", "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "http://www.ncbi.nlm.nih.gov/pubmed/28634592", "http://www.ncbi.nlm.nih.gov/pubmed/27088018"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 508, "offsetInEndSection": 595, "text": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 175, "offsetInEndSection": 442, "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 443, "offsetInEndSection": 575, "text": "Physicians should consider euglycemic diabetic ketoacidosis in the differential diagnosis of patients treated with SGLT2 inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 186, "offsetInEndSection": 391, "text": "Diabetic ketoacidosis usually manifests with high blood glucose more than 250\u2009mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250\u2009mg/dL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503"}, {"offsetInBeginSection": 392, "offsetInEndSection": 553, "text": "Normal blood glucose in such patients results in significant delay in diagnosis and management of diabetic ketoacidosis, thus increasing mortality and morbidity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503"}, {"offsetInBeginSection": 554, "offsetInEndSection": 664, "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592"}]}, {"id": "5a6e4136b750ff4455000045", "body": "Describe the Match BAM to VCF (MBV) method.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28186259"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "MBV: a method to solve sample mislabeling and detect technical bias in large combined genotype and sequencing assay datasets.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259"}, {"offsetInBeginSection": 0, "offsetInEndSection": 714, "text": "Motivation: Large genomic datasets combining genotype and sequence data, such as for expression quantitative trait loci (eQTL) detection, require perfect matching between both data types.Results: We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.Availability and Implementation: MBV is implemented in C\u2009++\u2009as an independent component of the QTLtools software package, the binary and source codes are freely available at https://qtltools.github.io/qtltools/ .Contact: olivier.delaneau@unige.ch or emmanouil.dermitzakis@unige.ch.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259"}]}, {"id": "5a897601fcd1d6a10c000008", "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10685800", "http://www.ncbi.nlm.nih.gov/pubmed/19762400", "http://www.ncbi.nlm.nih.gov/pubmed/22516994", "http://www.ncbi.nlm.nih.gov/pubmed/27365721", "http://www.ncbi.nlm.nih.gov/pubmed/23172751", "http://www.ncbi.nlm.nih.gov/pubmed/17477466", "http://www.ncbi.nlm.nih.gov/pubmed/16354890", "http://www.ncbi.nlm.nih.gov/pubmed/23647447", "http://www.ncbi.nlm.nih.gov/pubmed/8235662", "http://www.ncbi.nlm.nih.gov/pubmed/11480850"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Accurately describing changes in disease activity in Systemic Lupus Erythematosus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "OBJECTIVE: To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 369, "offsetInEndSection": 503, "text": "A clinician who did not know the patients or their SLEDAI scores evaluated each patient record and assigned a clinical activity level.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 651, "offsetInEndSection": 701, "text": "The SLEDAI score was calculated from the database.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 701, "offsetInEndSection": 794, "text": "RESULTS: SLEDAI scores described a range of clinical activity as recognized by the clinician.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 795, "offsetInEndSection": 885, "text": "Median SLEDAI scores ranged from 2 (inactive disease) to 8 (persistently active or flare).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 886, "offsetInEndSection": 981, "text": "When the clinician assessed the patient to be improved, the median SLEDAI score decreased by 2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 982, "offsetInEndSection": 1097, "text": "When the clinician assessed that the patient was experiencing a flare, the SLEDAI score increased by a median of 4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 1179, "offsetInEndSection": 1346, "text": "SLE: flare, an increase in SLEDAI > 3; improvement is a reduction in SLEDAI of > 3; persistently active disease is change in SLEDAI +/- 3; and remission a SLEDAI of 0.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400"}]}, {"id": "5a6f941eb750ff445500005b", "body": "What is the association between kidney donation risk of gestational complications?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27591246", "http://www.ncbi.nlm.nih.gov/pubmed/26090646", "http://www.ncbi.nlm.nih.gov/pubmed/18798006", "http://www.ncbi.nlm.nih.gov/pubmed/22252087", "http://www.ncbi.nlm.nih.gov/pubmed/26558022", "http://www.ncbi.nlm.nih.gov/pubmed/12351541", "http://www.ncbi.nlm.nih.gov/pubmed/26895841", "http://www.ncbi.nlm.nih.gov/pubmed/19353771", "http://www.ncbi.nlm.nih.gov/pubmed/27271097", "http://www.ncbi.nlm.nih.gov/pubmed/15240849"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Communicating the current knowledge of medical outcomes after live kidney donation necessary to support donor candidates in well informed decision-making requires grounding in perspectives of comparison.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 204, "offsetInEndSection": 326, "text": "Baseline risk (without donating), risk attributable to donation, and absolute risk (after donating) need to be considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 697, "offsetInEndSection": 830, "text": "In the first decade after donation, the risk of all-cause mortality and cardiovascular events is no higher than in healthy nondonors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 831, "offsetInEndSection": 964, "text": "Pregnancies in donors may incur attributable risk of gestational hypertension or preeclampsia (11% versus 5% incidence in one study).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Since the first living-donor kidney transplantation in 1954, more than half a million living kidney donations have occurred and research has advanced knowledge about long-term donor outcomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646"}, {"offsetInBeginSection": 296, "offsetInEndSection": 419, "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Assessment of the knowledge of living unrelated donors of the complications of kidney donation in Iran.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}, {"offsetInBeginSection": 88, "offsetInEndSection": 261, "text": "LURD transplantation (Tx) is performed in a controlled program, supervised by university Tx teams, and assisted by the Dialysis and Transplant Patient's Association (DATPA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}, {"offsetInBeginSection": 262, "offsetInEndSection": 411, "text": "This study evaluated the knowledge of donors about possible short- and long-term complications of kidney donation and the need for regular follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}, {"offsetInBeginSection": 1011, "offsetInEndSection": 1105, "text": "Eighty donors were not aware of the possible short- or long-term complications of nephrectomy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}]}, {"id": "5a6e4592b750ff4455000047", "body": "What is the 959 Nematode Genomes initiative?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24058822", "http://www.ncbi.nlm.nih.gov/pubmed/22044053"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 28, "text": "Toward 959 nematode genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "The sequencing of the complete genome of the nematode Caenorhabditis elegans was a landmark achievement and ushered in a new era of whole-organism, systems analyses of the biology of this powerful model organism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 213, "offsetInEndSection": 369, "text": "The success of the C. elegans genome sequencing project also inspired communities working on other organisms to approach genome sequencing of their species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 370, "offsetInEndSection": 518, "text": "The phylum Nematoda is rich and diverse and of interest to a wide range of research fields from basic biology through ecology and parasitic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 1003, "offsetInEndSection": 1194, "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The diversity of biology in nematodes is reflected in the diversity of their genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 483, "offsetInEndSection": 709, "text": "Wide sampling across nematode diversity allows phylogenetically informed formulation of research hypotheses, identification of core features shared by all species or important evolutionary novelties present in isolated clades.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 710, "offsetInEndSection": 853, "text": "Many nematode species have been investigated through the use of the expressed sequence tag approach, which samples from the transcribed genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 1379, "offsetInEndSection": 1459, "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 519, "offsetInEndSection": 713, "text": "For all these communities, it is now clear that access to genome scale data will be key to advancing understanding, and in the case of parasites, developing new ways to control or cure diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}]}, {"id": "5a897927fcd1d6a10c00000a", "body": "What does A1C measure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20923490", "http://www.ncbi.nlm.nih.gov/pubmed/18030866", "http://www.ncbi.nlm.nih.gov/pubmed/16336550", "http://www.ncbi.nlm.nih.gov/pubmed/23990520", "http://www.ncbi.nlm.nih.gov/pubmed/18509211", "http://www.ncbi.nlm.nih.gov/pubmed/28843470", "http://www.ncbi.nlm.nih.gov/pubmed/22301123", "http://www.ncbi.nlm.nih.gov/pubmed/24511995", "http://www.ncbi.nlm.nih.gov/pubmed/20861123", "http://www.ncbi.nlm.nih.gov/pubmed/28964455"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Does A1c consistently reflect mean plasma glucose?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "BACKGROUND: A1c, a surrogate measure of glycemic control, is known to have a strong linear correlation with mean plasma glucose (MPG) when analyzed in populations of patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 176, "offsetInEndSection": 356, "text": "However, clinically significant intersubject variability in this relationship exists, which suggests that A1c measurements may not reflect actual glycemic control in some patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 357, "offsetInEndSection": 498, "text": "In the present study we explored the extent to which A1c accurately represents glycemic control, as measured by MPG, for individual patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 498, "offsetInEndSection": 704, "text": "METHODS: Data were pooled from randomized clinical trials in which A1c and self-monitored plasma glucose (SMPG) profiles were collected by patients with Type 2 diabetes treated with insulin analog regimens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 752, "offsetInEndSection": 830, "text": "Distributions of MPG were analyzed for patients within similar ranges of A1c (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 830, "offsetInEndSection": 934, "text": "RESULTS: Substantial proportions of patients had clinically significant differences between A1c and MPG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 935, "offsetInEndSection": 1029, "text": "For example, among 260 patients with A1c between 6.5% and 7.5%, 10% had MPG levels 9.5 mmol/L.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 1090, "offsetInEndSection": 1202, "text": "CONCLUSIONS: In the absence of SMPG, A1c may inadequately represent glycemic control for many diabetic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "One size does not fit all: the need for a continuous measure for glycemic control in diabetes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866"}]}, {"id": "5a6f98e6b750ff445500005d", "body": "Which ligament is most commonly injured in dashboard injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3425783", "http://www.ncbi.nlm.nih.gov/pubmed/7377448", "http://www.ncbi.nlm.nih.gov/pubmed/22890899", "http://www.ncbi.nlm.nih.gov/pubmed/27623865", "http://www.ncbi.nlm.nih.gov/pubmed/15062581", "http://www.ncbi.nlm.nih.gov/pubmed/15474227", "http://www.ncbi.nlm.nih.gov/pubmed/20110155", "http://www.ncbi.nlm.nih.gov/pubmed/18980604", "http://www.ncbi.nlm.nih.gov/pubmed/21257845", "http://www.ncbi.nlm.nih.gov/pubmed/19468882"], "snippets": [{"offsetInBeginSection": 394, "offsetInEndSection": 437, "text": "The athletic activity at injury was varied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 438, "offsetInEndSection": 574, "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1458, "text": "Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Occult knee ligament injuries associated with femoral shaft fractures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}, {"offsetInBeginSection": 325, "offsetInEndSection": 476, "text": "The high incidence (48%) of ipsilateral knee ligament damage, particularly of a severe nature (30%) evident at followup (mean 24.5 months) is alarming.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}, {"offsetInBeginSection": 477, "offsetInEndSection": 591, "text": "In the 26 cases of knee ligament damage, the mean time from injury to documentation of instability is 12.8 months.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}, {"offsetInBeginSection": 671, "offsetInEndSection": 764, "text": "The majority are dashboard impacts treated in balanced traction with subsequent case bracing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}, {"offsetInBeginSection": 765, "offsetInEndSection": 946, "text": "The anterior cruciate ligament (50%) is most often injured followed by the medial collateral ligament (31%), lateral collateral ligament (13%), and posterior cruciate ligament (6%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Structure and function, injury, pathology, and treatment of the medial collateral ligament of the knee.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899"}]}, {"id": "5a6e49a4b750ff445500004b", "body": "Is LDB1-mediated enhancer looping dependent on cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28520978"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "LDB1-mediated enhancer looping can be established independent of mediator and cohesin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Mechanistic studies in erythroid cells indicate that LDB1, as part of a GATA1/TAL1/LMO2 complex, brings erythroid-expressed genes into proximity with enhancers for transcription activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 282, "offsetInEndSection": 450, "text": "Here we tested the contributions of the RNA Pol II pre-initiation complex (PIC), mediator and cohesin to establishment of locus control region (LCR)/\u03b2-globin proximity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 780, "offsetInEndSection": 1018, "text": "To separate the roles of LDB1 and mediator in LCR looping, we expressed a looping-competent but transcription-activation deficient form of LDB1 in LDB1 knock down cells: LCR/\u03b2-globin proximity was restored without mediator core occupancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1166, "text": "Further, Cas9-directed tethering of mutant LDB1 to the \u03b2-globin promoter forced LCR loop formation in the absence of mediator or cohesin occupancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 1167, "offsetInEndSection": 1359, "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 1360, "offsetInEndSection": 1488, "text": "Thus, lineage specific factors largely mediate enhancer-promoter looping in erythroid cells independent of mediator and cohesin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 451, "offsetInEndSection": 637, "text": "CRISPR/Cas9 editing of the \u03b2-globin promoter to eliminate the RNA Pol II PIC by deleting the TATA-box resulted in loss of transcription, but enhancer-promoter interaction was unaffected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 638, "offsetInEndSection": 779, "text": "Additional deletion of the promoter GATA1 site eliminated LDB1 complex and mediator occupancy and resulted in loss of LCR/\u03b2-globin proximity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 190, "offsetInEndSection": 281, "text": "The role of co-activators in establishing this long-range interaction is poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}]}, {"id": "5a897a06fcd1d6a10c00000b", "body": "What is the normal body temperature in dogs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/495147", "http://www.ncbi.nlm.nih.gov/pubmed/25854787", "http://www.ncbi.nlm.nih.gov/pubmed/2759725", "http://www.ncbi.nlm.nih.gov/pubmed/28216687", "http://www.ncbi.nlm.nih.gov/pubmed/21102554", "http://www.ncbi.nlm.nih.gov/pubmed/22058348", "http://www.ncbi.nlm.nih.gov/pubmed/9656028", "http://www.ncbi.nlm.nih.gov/pubmed/11913416", "http://www.ncbi.nlm.nih.gov/pubmed/19575699", "http://www.ncbi.nlm.nih.gov/pubmed/6617751"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "On the mechanism of central effect of thyroxine on body temperature in dogs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 251, "offsetInEndSection": 355, "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 387, "offsetInEndSection": 486, "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Measurement of body temperature in 300 dogs with a novel noncontact infrared thermometer on the cornea in comparison to a standard rectal digital thermometer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "OBJECTIVE: To assess the accuracy of obtaining body temperatures in dogs with a noncontact infrared thermometer (NCIT) on the cornea compared with a rectal digital thermometer (RDT).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 260, "offsetInEndSection": 342, "text": "ANIMALS: Three hundred dogs presented with low, normal, or high body temperatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1418, "text": "Although the use of the NCIT yields faster results and is significantly more comfortable for the dog than the RDT measurement, it cannot be recommended in dogs at this time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Plasma-cortisol levels in experimental heatstroke in dogs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2759725"}, {"offsetInBeginSection": 152, "offsetInEndSection": 318, "text": "Thirty-three unanesthetized dogs were tested under two sets of climatic conditions: comfort conditions and hot-dry climatic conditions, half of them while exercising.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2759725"}]}, {"id": "5a70d12899e2c3af26000001", "body": "List symptoms of Heerfordt syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17637529", "http://www.ncbi.nlm.nih.gov/pubmed/20184241", "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "http://www.ncbi.nlm.nih.gov/pubmed/22565854", "http://www.ncbi.nlm.nih.gov/pubmed/25087562", "http://www.ncbi.nlm.nih.gov/pubmed/26885424", "http://www.ncbi.nlm.nih.gov/pubmed/25685372", "http://www.ncbi.nlm.nih.gov/pubmed/2307892", "http://www.ncbi.nlm.nih.gov/pubmed/21706840", "http://www.ncbi.nlm.nih.gov/pubmed/27549672"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Sarcoidosis (Heerfordt syndrome): a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "We report the case of a 22-year-old woman who is suspected of having primary Sj\u00f6gren s syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 302, "offsetInEndSection": 400, "text": "Sj\u00f6gren s syndrome was suspected at that stage, and the serologic and specific analysis were done.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 401, "offsetInEndSection": 528, "text": "All these tests didn t find any autoimmune or visceral features typical of Sj\u00f6gren s syndrome and autoantibodies were negative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 771, "offsetInEndSection": 897, "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "[A case of familial sarcoidosis accompanied by Heerfordt syndrome with pericardial effusion].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 638, "offsetInEndSection": 693, "text": "Various clinical symptoms indicated Heerfordt syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Heerfordt syndrome with unilateral facial nerve palsy: a rare presentation of sarcoidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "BACKGROUND: Heerfordt syndrome is rare and is characterized by fever, uveitis, parotid gland enlargement, and facial nerve palsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397"}]}, {"id": "5a6e4b72b750ff445500004c", "body": "Is there any link between ERCC1-XPF and cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28368372", "http://www.ncbi.nlm.nih.gov/pubmed/14512883", "http://www.ncbi.nlm.nih.gov/pubmed/20518486", "http://www.ncbi.nlm.nih.gov/pubmed/24158589", "http://www.ncbi.nlm.nih.gov/pubmed/14706347", "http://www.ncbi.nlm.nih.gov/pubmed/10882712", "http://www.ncbi.nlm.nih.gov/pubmed/12509251", "http://www.ncbi.nlm.nih.gov/pubmed/11160918", "http://www.ncbi.nlm.nih.gov/pubmed/12202770", "http://www.ncbi.nlm.nih.gov/pubmed/15199134"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "ERCC1-XPF cooperates with CTCF and cohesin to\u00a0facilitate the developmental silencing of imprinted\u00a0genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 128, "offsetInEndSection": 521, "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 522, "offsetInEndSection": 804, "text": "Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 805, "offsetInEndSection": 1050, "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Characterization of premature liver polyploidy in DNA repair (Ercc1)-deficient mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "ERCC1-XPF is the endonuclease that cuts 5' of the damage in nucleotide excision repair (NER).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 94, "offsetInEndSection": 211, "text": "Unlike other NER proteins, ERCC1-XPF is also involved in recombination and the repair of DNA interstrand cross-links.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 328, "offsetInEndSection": 522, "text": "To understand the link between DNA repair deficiency and polyploidy we have compared the premature polyploidy in Ercc1 null liver with the normal development of polyploidy in aging control mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 1010, "offsetInEndSection": 1211, "text": "We suggest that the more rapid accumulation of DNA damage in Ercc1 null liver leads to an increase in p21 levels, but that there is not a simple direct link between p21 levels and premature polyploidy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 1475, "offsetInEndSection": 1586, "text": "In conclusion, the premature polyploidy in Ercc1-deficient liver differs from the normal aging-related process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}]}, {"id": "5a8afbf2fcd1d6a10c00001c", "body": "In quadruped mammals, what bones make up the stifle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17266668", "http://www.ncbi.nlm.nih.gov/pubmed/19378290", "http://www.ncbi.nlm.nih.gov/pubmed/21113010", "http://www.ncbi.nlm.nih.gov/pubmed/19378269", "http://www.ncbi.nlm.nih.gov/pubmed/24323904", "http://www.ncbi.nlm.nih.gov/pubmed/25709597", "http://www.ncbi.nlm.nih.gov/pubmed/23554931", "http://www.ncbi.nlm.nih.gov/pubmed/16226434", "http://www.ncbi.nlm.nih.gov/pubmed/23977887", "http://www.ncbi.nlm.nih.gov/pubmed/3218668"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Comparative anatomy of the meniscofemoral ligament in humans and some domestic mammals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "The purpose of this study was to investigate the presence, position and relative sizes of the meniscofemoral ligaments (MFL) in three quadrupeds and humans and relate these to the caudal slope of the lateral tibial plateau.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1358, "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Olecranon orientation as an indicator of elbow joint angle in the stance phase, and estimation of forelimb posture in extinct quadruped animals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 431, "offsetInEndSection": 574, "text": "This study presents a procedure that how the elbow joint angles of extinct quadruped mammals can be inferred from osteological characteristics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 835, "offsetInEndSection": 918, "text": "At this angle, the major extensor muscles maximize their torque at the elbow joint.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1127, "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1375, "text": "By estimating the elbow joint angle, it is inferred that Desmostylus would have had more upright forelimbs than Paleoparadoxia, because their elbow joint angles during the stance phase were approximately 165 degrees and 130 degrees , respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 1376, "offsetInEndSection": 1504, "text": "Difference in elbow joint angles between these two genera suggests possible differences in stance and gait of these two mammals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Functional morphology and three-dimensional kinematics of the thoraco-lumbar region of the spine of the two-toed sloth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010"}]}, {"id": "5a70d42899e2c3af26000002", "body": "Mutation of which gene causes arterial tortuosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18818946", "http://www.ncbi.nlm.nih.gov/pubmed/18774132", "http://www.ncbi.nlm.nih.gov/pubmed/16550171", "http://www.ncbi.nlm.nih.gov/pubmed/19622975", "http://www.ncbi.nlm.nih.gov/pubmed/22488877", "http://www.ncbi.nlm.nih.gov/pubmed/22734312", "http://www.ncbi.nlm.nih.gov/pubmed/19028722", "http://www.ncbi.nlm.nih.gov/pubmed/19781076", "http://www.ncbi.nlm.nih.gov/pubmed/17935213", "http://www.ncbi.nlm.nih.gov/pubmed/20735855"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "A novel non-sense mutation in the SLC2A10 gene of an arterial tortuosity syndrome patient of Kurdish origin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Arterial tortuosity syndrome (ATS) is a rare autosomal recessive disorder in which patients display tortuosity of arteries in addition to hyperextensible skin, joint laxity, and other connective tissue features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 212, "offsetInEndSection": 269, "text": "This syndrome is caused by mutations in the SLC2A10 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 270, "offsetInEndSection": 478, "text": "In this article we describe an ATS girl of Kurdish origin who, in addition to arterial tortuosity and connective tissue features, displays stomach displacement within the thorax and bilateral hip dislocation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1041, "text": "We conclude that patients of Kurdish origin who display arterial tortuosity associated with skin hyperextensibility, joint hypermobility, and characteristic facial features may carry mutations in the SLC2A10 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "A novel missense and a recurrent mutation in SLC2A10 gene of patients affected with arterial tortuosity syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Arterial tortuosity syndrome is an autosomal recessive disorder characterized by severe tortuosity of greater and systemic arteries in affected individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 310, "offsetInEndSection": 425, "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 426, "offsetInEndSection": 617, "text": "We describe seven patients of two unrelated Saudi Arabian families who display tortuosity, dilatation and stenosis of arteries, pulmonary hypertension and other cardiovascular manifestations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1407, "text": "The present study suggests that there exists an intra- and inter-familial phenotypic variability in arterial tortuosity patients carrying identical or different mutations in SLC2A10 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}]}, {"id": "5a6f940bb750ff445500005a", "body": "What is the aim of the 4D nucleome project?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28905911", "http://www.ncbi.nlm.nih.gov/pubmed/29168505"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 24, "text": "The 4D nucleome project.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "Corrigendum: The 4D nucleome project.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168505"}, {"offsetInBeginSection": 246, "offsetInEndSection": 470, "text": "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 471, "offsetInEndSection": 692, "text": "Validated experimental technologies will be combined with biophysical approaches to generate quantitative models of spatial genome organization in different biological states, both in cell populations and in single cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 26, "offsetInEndSection": 51, "text": "DOI: 10.1038/nature23884.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168505"}]}, {"id": "5a8b1264fcd1d6a10c00001d", "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10517025", "http://www.ncbi.nlm.nih.gov/pubmed/24561899", "http://www.ncbi.nlm.nih.gov/pubmed/18945093", "http://www.ncbi.nlm.nih.gov/pubmed/18944618", "http://www.ncbi.nlm.nih.gov/pubmed/18624637", "http://www.ncbi.nlm.nih.gov/pubmed/24909710", "http://www.ncbi.nlm.nih.gov/pubmed/18943589", "http://www.ncbi.nlm.nih.gov/pubmed/24024636", "http://www.ncbi.nlm.nih.gov/pubmed/9237400", "http://www.ncbi.nlm.nih.gov/pubmed/28956188"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Tomatinase from Fusarium oxysporum f. sp.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 91, "offsetInEndSection": 197, "text": "Saponins are plant glycosides that may provide a preformed chemical barrier against phytopathogenic fungi.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 198, "offsetInEndSection": 223, "text": "Fusarium oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 224, "offsetInEndSection": 382, "text": "lycopersici and other tomato pathogens produce extracellular enzymes known as tomatinases, which deglycosylate alpha-tomatine to yield less toxic derivatives.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 383, "offsetInEndSection": 517, "text": "We have cloned and characterized the cDNA and genomic DNA encoding tomatinase from the vascular pathogen of tomato F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 531, "offsetInEndSection": 692, "text": "This gene encodes a protein (FoTom1) with no amino acid sequence homology to any previously described saponinase, including tomatinase from Septoria lycopersici.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1062, "text": "Tomatinase from F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1063, "offsetInEndSection": 1149, "text": "lycopersici is encoded by a single gene whose expression is induced by alpha-tomatine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1458, "text": "The tomatinase gene is expressed in planta in both roots and stems throughout the entire disease cycle of F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "In vitro antifugal activity of medicinal plant extract against Fusarium oxysporum f. sp.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899"}]}, {"id": "5a70d43b99e2c3af26000003", "body": "Does prolactinoma increase osteoporosis risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11293923", "http://www.ncbi.nlm.nih.gov/pubmed/20205855", "http://www.ncbi.nlm.nih.gov/pubmed/22553947", "http://www.ncbi.nlm.nih.gov/pubmed/17578827", "http://www.ncbi.nlm.nih.gov/pubmed/26319389"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923"}, {"offsetInBeginSection": 1145, "offsetInEndSection": 1323, "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Prolactinoma presenting as chronic anaemia with osteoporosis: a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 154, "offsetInEndSection": 249, "text": "Six years later, he was evaluated and diagnosed with a prolactinoma and resultant osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 250, "offsetInEndSection": 378, "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1048, "text": "Dual X-ray absorptiometry revealed osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "The risk of osteopenia in premenopausal women with various sellar tumors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "OBJECTIVE: Patients with prolactinoma seem to be at high risk for osteopenia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947"}, {"offsetInBeginSection": 78, "offsetInEndSection": 185, "text": "However, whether patients with various pathological sellar tumors have risk for osteopenia remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947"}, {"offsetInBeginSection": 601, "offsetInEndSection": 723, "text": "RESULTS: Compared to the matched controls, BMD of patients with prolactinoma or craniopharyngioma significantly decreased.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947"}]}, {"id": "5a6fa31ab750ff445500005e", "body": "Which method has been developed for assignment of enhancers to target genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29070071"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "McEnhancer: predicting gene expression via semi-supervised assignment of enhancers to target genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Transcriptional enhancers regulate spatio-temporal gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 68, "offsetInEndSection": 177, "text": "While genomic assays can identify putative enhancers en masse, assigning target genes is a complex challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 178, "offsetInEndSection": 393, "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 611, "offsetInEndSection": 752, "text": "Our model provides a general framework to link globally identified enhancers to targets and contributes to deciphering the regulatory genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 394, "offsetInEndSection": 610, "text": "Predicted expression patterns were 73-98% accurate, predicted assignments showed strong Hi-C interaction enrichment, enhancer-associated histone modifications were evident, and known functional motifs were recovered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}]}, {"id": "5a8dc6b4fcd1d6a10c000026", "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27753694", "http://www.ncbi.nlm.nih.gov/pubmed/23051720", "http://www.ncbi.nlm.nih.gov/pubmed/21936033", "http://www.ncbi.nlm.nih.gov/pubmed/27570643", "http://www.ncbi.nlm.nih.gov/pubmed/21484967", "http://www.ncbi.nlm.nih.gov/pubmed/17129810", "http://www.ncbi.nlm.nih.gov/pubmed/25685145", "http://www.ncbi.nlm.nih.gov/pubmed/17461487", "http://www.ncbi.nlm.nih.gov/pubmed/28868386", "http://www.ncbi.nlm.nih.gov/pubmed/26631943"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "BACKGROUND: Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 104, "offsetInEndSection": 315, "text": "Although these findings have significantly advanced our insight into IBD biology, there has been little progress in translating this knowledge toward clinical practice, like more cost-efficient drug development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 316, "offsetInEndSection": 423, "text": "Our aim was to use genetic knowledge to identify drugs that warrant further investigation in IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 423, "offsetInEndSection": 596, "text": "METHODS: We hypothesized that proteins encoded by IBD candidate genes are potential IBD drug targets because genetic information can increase successful drug identification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 935, "offsetInEndSection": 1021, "text": "RESULTS: We have identified 113 drugs that could potentially be used in IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1277, "text": "Fourteen are known IBD drugs, 48 drugs have been, or are being investigated in IBD, 19 are being used or being investigated in other inflammatory disorders treatment, and 32 are investigational new drugs that have not yet been registered for clinical use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1277, "offsetInEndSection": 1385, "text": "CONCLUSIONS: We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1505, "text": "Furthermore, we show that Food and Drug Administration-approved drugs could possibly be repositioned for IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1506, "offsetInEndSection": 1602, "text": "We also identify investigational new drugs that warrant further investigation for IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}]}, {"id": "5a70e4b399e2c3af26000008", "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28688001", "http://www.ncbi.nlm.nih.gov/pubmed/28800195", "http://www.ncbi.nlm.nih.gov/pubmed/28807904", "http://www.ncbi.nlm.nih.gov/pubmed/28412293", "http://www.ncbi.nlm.nih.gov/pubmed/29020583", "http://www.ncbi.nlm.nih.gov/pubmed/28818546"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 15, "offsetInEndSection": 160, "text": "OBJECTIVE: Glecaprevir and pibrentasvir are pangenotypic direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 161, "offsetInEndSection": 314, "text": "The aim of the present study was to evaluate the drug-drug interaction and safety of glecaprevir and pibrentasvir coadministration in healthy volunteers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 556, "offsetInEndSection": 765, "text": "Intensive blood sampling was performed on Days 1, 7, 8, and 14, and pharmacokinetic interactions were assessed using a repeated measures analysis of glecaprevir and pibrentasvir maximum plasma concentration (C", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 766, "offsetInEndSection": 865, "text": "RESULTS: Coadministration of glecaprevir 400\u00a0mg increased pibrentasvir 120 and 40\u00a0mg steady-state C", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1126, "text": "CONCLUSIONS: Coadministration of pibrentasvir 120\u00a0mg with glecaprevir doses up to 400\u00a0mg resulted in increases in pibrentasvir exposures without significant changes in glecaprevir exposures in the absence of any clinically significant laboratory abnormalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 161, "offsetInEndSection": 391, "text": "The aim of the present studies was to assess the effect of race and ethnicity (white, Han Chinese, Japanese) on the pharmacokinetics and safety of multiple oral doses of glecaprevir and pibrentasvir given alone and in combination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 555, "offsetInEndSection": 775, "text": "Glecaprevir (100, 200, 300, or 700\u00a0mg once daily) and pibrentasvir (80, 120, or 160\u00a0mg once daily) were administered alone for 7 days followed by the combination of both direct-acting antiviral agents for another 7 days.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}]}, {"id": "5a6fa417b750ff445500005f", "body": "Describe the RNA Centric Annotation System (RCAS)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28334930"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "RCAS: an RNA centric annotation system for transcriptome-wide regions of interest.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "In the field of RNA, the technologies for studying the transcriptome have created a tremendous potential for deciphering the puzzles of the RNA biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 153, "offsetInEndSection": 287, "text": "Along with the excitement, the unprecedented volume of RNA related omics data is creating great challenges in bioinformatics analyses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 288, "offsetInEndSection": 536, "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 537, "offsetInEndSection": 660, "text": "The design of RCAS is modular, which enables flexible usage and convenient integration with other bioinformatics workflows.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 799, "offsetInEndSection": 965, "text": "The application of RCAS on published datasets shows that RCAS is not only able to reproduce published findings but also helps generate novel knowledge and hypotheses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1207, "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 1337, "offsetInEndSection": 1449, "text": "RCAS is available at http://bioconductor.org/packages/release/bioc/html/RCAS.html and http://rcas.mdc-berlin.de.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 661, "offsetInEndSection": 798, "text": "RCAS is an R/Bioconductor package but we also created graphical user interfaces including a Galaxy wrapper and a stand-alone web service.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 1208, "offsetInEndSection": 1336, "text": "In addition, the array of different interfaces and deployment options adds the convenience of use for different levels of users.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}]}, {"id": "5a76018c83b0d9ea6600000e", "body": "List the ten types of conjoined twins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1412053", "http://www.ncbi.nlm.nih.gov/pubmed/24193193", "http://www.ncbi.nlm.nih.gov/pubmed/8787375", "http://www.ncbi.nlm.nih.gov/pubmed/12483645", "http://www.ncbi.nlm.nih.gov/pubmed/29064095", "http://www.ncbi.nlm.nih.gov/pubmed/19060714", "http://www.ncbi.nlm.nih.gov/pubmed/16122113", "http://www.ncbi.nlm.nih.gov/pubmed/19361646", "http://www.ncbi.nlm.nih.gov/pubmed/16677900", "http://www.ncbi.nlm.nih.gov/pubmed/27369817"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Conjoined twins: theoretical embryologic basis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "A theoretical basis for the embryology of conjoined twins was formulated from clinical experience with ten cases and extensive review of pertinent embryologic and clinical literature, including over 500 cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 210, "offsetInEndSection": 421, "text": "Regarding the age old question of fusion or fission, it is concluded that there is no known embryologic process by which conjoined twins can be formed by fission but firm evidence to support fusion in all cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 547, "offsetInEndSection": 703, "text": "Intact ectoderm will not fuse to intact ectoderm, and all seven types of conjoined twins are explained by seven possible sites of union in the early embryo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Diagnostic techniques and criteria for first-trimester conjoined twin documentation: a review of the literature illustrated by three recent cases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "OBJECTIVES: Conjoined twins are rare.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 223, "offsetInEndSection": 405, "text": "The aim of this review was to explore imaging techniques used in the first-trimester diagnosis of conjoined twins and provide a systematic diagnostic table for making this diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 405, "offsetInEndSection": 553, "text": "DESIGN: A PubMed literature search was performed using the terms ultrasound, Doppler, MRI, and CT combined with first-trimester and conjoined twins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 670, "offsetInEndSection": 792, "text": "RESULTS: The different types of conjoined twins are summarized in a table for practical use during ultrasound examination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 793, "offsetInEndSection": 875, "text": "In evaluating conjoined twins, 2-dimensional ultrasound is the criterion standard.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}]}, {"id": "5a70e6e899e2c3af26000009", "body": "What is the mechanism of action of Fremanezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28972120", "http://www.ncbi.nlm.nih.gov/pubmed/28642283"], "snippets": [{"offsetInBeginSection": 742, "offsetInEndSection": 1128, "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1349, "offsetInEndSection": 1471, "text": "These findings identify A\u03b4 meningeal nociceptors as a likely site of action of fremanezumab in the prevention of headache.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1472, "offsetInEndSection": 1773, "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}, {"offsetInBeginSection": 440, "offsetInEndSection": 570, "text": "The purpose of this study was to better understand how the CGRP-mAb fremanezumab (TEV-48125) modulates meningeal sensory pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}, {"offsetInBeginSection": 571, "offsetInEndSection": 900, "text": "To answer this question, we used single-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab on spontaneous and evoked activity in naive and cortical spreading depression (CSD)-sensitized trigeminovascular neurons in the spinal trigeminal nucleus of anesthetized male and female rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}, {"offsetInBeginSection": 1195, "offsetInEndSection": 1312, "text": "In addition, when given sufficient time, fremanezumab prevents the activation and sensitization of HT neurons by CSD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}, {"offsetInBeginSection": 452, "offsetInEndSection": 741, "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1348, "text": "Fremanezumab pretreatment selectively inhibited the responsiveness of A\u03b4 neurons, but not C-fiber neurons, as reflected in a decrease in the percentage of neurons that showed activation by cortical spreading depression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1194, "text": "The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons, but not wide-dynamic range trigeminovascular neurons, and that the inhibitory effects on the neurons were limited to their activation from the intracranial dura but not facial skin or cornea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}]}, {"id": "5a6fa61ab750ff4455000060", "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27366148"], "snippets": [{"offsetInBeginSection": 4, "offsetInEndSection": 51, "text": "SSR: Microsatellite Finder and Primer Designer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 150, "offsetInEndSection": 278, "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 849, "offsetInEndSection": 926, "text": "FullSSR simplifies the detection of SSRs and primer design on a big data set.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Microsatellites are genomic sequences comprised of tandem repeats of short nucleotide motifs widely used as molecular markers in population genetics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 578, "offsetInEndSection": 653, "text": "FullSSR performance was compared against other similar SSR search programs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1146, "text": "The command line interface of FullSSR was intended to be used as part of genomic analysis tools pipeline; however, it can be used as a stand-alone program because the results are easily interpreted for a nonexpert user.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 744, "offsetInEndSection": 848, "text": "In addition, results can be affected by the analyzed sequences because of differences among the genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 654, "offsetInEndSection": 743, "text": "The results of the use of this kind of approach depend on the parameters set by the user.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 279, "offsetInEndSection": 577, "text": "The software was tested with 2000 sequences of Oryza sativa shotgun sequencing project from the National Center of Biotechnology Information Trace Archive and with partial genome sequencing with ROCHE 454\u00ae from Caiman latirostris, Salvator merianae, Aegla platensis, and Zilchiopsis collastinensis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}]}, {"id": "5a70e88699e2c3af2600000a", "body": "Describe mechanism of action of Nusinersen.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27939059", "http://www.ncbi.nlm.nih.gov/pubmed/28884620"], "snippets": [{"offsetInBeginSection": 1730, "offsetInEndSection": 1796, "text": "The study is registered at ClinicalTrials.gov, number NCT01839656.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 2207, "offsetInEndSection": 2422, "text": "INTERPRETATION: Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 2423, "offsetInEndSection": 2563, "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 180, "offsetInEndSection": 305, "text": "This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, Spinraza", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620"}, {"offsetInBeginSection": 346, "offsetInEndSection": 625, "text": "METHODS: This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 137, "offsetInEndSection": 346, "text": "Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 1493, "offsetInEndSection": 1632, "text": "HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Nusinersen for the treatment of spinal muscular atrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620"}, {"offsetInBeginSection": 2563, "offsetInEndSection": 2610, "text": "FUNDING: Ionis Pharmaceuticals, Inc and Biogen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}]}, {"id": "5a6fa9f7b750ff4455000061", "body": "Describe Click-PEGylation", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28366801", "http://www.ncbi.nlm.nih.gov/pubmed/22988919", "http://www.ncbi.nlm.nih.gov/pubmed/18590303", "http://www.ncbi.nlm.nih.gov/pubmed/28205176", "http://www.ncbi.nlm.nih.gov/pubmed/27213717", "http://www.ncbi.nlm.nih.gov/pubmed/23106398", "http://www.ncbi.nlm.nih.gov/pubmed/22243664", "http://www.ncbi.nlm.nih.gov/pubmed/23613182", "http://www.ncbi.nlm.nih.gov/pubmed/21618993", "http://www.ncbi.nlm.nih.gov/pubmed/9279893"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Click-PEGylation - A mobility shift approach to assess the redox state of cysteines in candidate proteins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 1551, "offsetInEndSection": 1856, "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 2068, "offsetInEndSection": 2171, "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon \u03b2-1b by site-specific PEGylation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22988919"}, {"offsetInBeginSection": 381, "offsetInEndSection": 612, "text": "To this end, we describe the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC, a click chemistry reaction) for site-specific PEGylation of interferon \u03b2-1b (IFNb) containing azidohomoalanine (Aha) at the N-terminus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22988919"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "PEGylation of porous silicon using click chemistry.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 159, "offsetInEndSection": 250, "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 566, "offsetInEndSection": 747, "text": "This work highlights the simplicity of click-chemistry-based functionalization in tailoring the porous silicon surface chemistry and controlling protein-porous silicon interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Determining the Topology of Membrane-Bound Proteins Using PEGylation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176"}, {"offsetInBeginSection": 188, "offsetInEndSection": 384, "text": "Here, we describe the method of PEGylation, which uses a cysteine-reactive molecule, maleimide polyethylene glycol (mPEG), to determine the cytosolic accessibility of introduced cysteine residues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176"}]}, {"id": "5a70ea8299e2c3af2600000b", "body": "Does Evolocumab improve cognitive function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28207168", "http://www.ncbi.nlm.nih.gov/pubmed/28813214"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 138, "offsetInEndSection": 272, "text": "Similar questions were raised regarding proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9i) and neurocognitive function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 273, "offsetInEndSection": 387, "text": "No prospectively designed study has evaluated the relationship between long-term PCSK9i use and cognition changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 388, "offsetInEndSection": 680, "text": "Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 681, "offsetInEndSection": 820, "text": "Key additional exclusion criteria for EBBINGHAUS were dementia, cognitive impairment, or other significant mental or neurological disorder.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 821, "offsetInEndSection": 1092, "text": "Cognitive testing was performed using the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at baseline, weeks 24 and 48, every 48 weeks thereafter, and study end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 1093, "offsetInEndSection": 1186, "text": "The primary endpoint was spatial working memory strategy index of executive function (SWMSI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1314, "text": "The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Cognitive Function in a Randomized Trial of Evolocumab.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}, {"offsetInBeginSection": 276, "offsetInEndSection": 500, "text": "Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}]}, {"id": "5a75dff883b0d9ea66000003", "body": "Name curated data resources for ChIP-seq data", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27789702", "http://www.ncbi.nlm.nih.gov/pubmed/26969372", "http://www.ncbi.nlm.nih.gov/pubmed/22495751", "http://www.ncbi.nlm.nih.gov/pubmed/24253304", "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "http://www.ncbi.nlm.nih.gov/pubmed/29069466", "http://www.ncbi.nlm.nih.gov/pubmed/19892823", "http://www.ncbi.nlm.nih.gov/pubmed/21097880", "http://www.ncbi.nlm.nih.gov/pubmed/22827163", "http://www.ncbi.nlm.nih.gov/pubmed/27863463"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 236, "offsetInEndSection": 527, "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 528, "offsetInEndSection": 751, "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 752, "offsetInEndSection": 901, "text": "All the data have been carefully curated and processed with a streamlined analysis pipeline and evaluated with comprehensive quality control metrics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 902, "offsetInEndSection": 996, "text": "We have also created a user-friendly web server for data query, exploration and visualization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1188, "text": "The resulting Cistrome DB (Cistrome Data Browser), available online at http://cistrome.org/db, is expected to become a valuable resource for transcriptional and epigenetic regulation studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Integrating RNA-seq and ChIP-seq data to characterize long non-coding RNAs in Drosophila melanogaster.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 528, "offsetInEndSection": 695, "text": "Moreover, there is an increasing interest in the use of ChIP-seq data (H3K4me3, H3K36me3 and Pol II) to detect signatures of active transcription for reported lncRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 695, "offsetInEndSection": 879, "text": "RESULTS: We have developed a computational approach to identify new lncRNAs from two tissue-specific RNA-seq datasets using the poly(A)-enriched and the ribo-zero method, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1031, "text": "In our results, we identified 462 novel lncRNA transcripts, which we combined with 4137 previously published lncRNA transcripts into a curated dataset.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}]}, {"id": "5a72284b2dc08e987e000001", "body": "Can radius fracture cause carpal tunnel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29169594", "http://www.ncbi.nlm.nih.gov/pubmed/23026468", "http://www.ncbi.nlm.nih.gov/pubmed/21786553", "http://www.ncbi.nlm.nih.gov/pubmed/21505639", "http://www.ncbi.nlm.nih.gov/pubmed/26566562", "http://www.ncbi.nlm.nih.gov/pubmed/27454517", "http://www.ncbi.nlm.nih.gov/pubmed/11514776"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Carpal Tunnel Syndrome and Distal Radius Fractures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 114, "offsetInEndSection": 167, "text": "Acute CTS requires an emergent carpal tunnel release.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 168, "offsetInEndSection": 313, "text": "Many patients with transient CTS after distal radius fracture do not require surgical release of the carpal tunnel once the fracture is repaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 314, "offsetInEndSection": 441, "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 442, "offsetInEndSection": 600, "text": "For patients with delayed CTS after a distal radius fracture, all possible causes of nerve compression should be considered and addressed in standard fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Carpal tunnel syndrome after distal radius fracture.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Carpal tunnel syndrome is a common condition and is a well-recognized phenomenon following a distal radius fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 193, "offsetInEndSection": 329, "text": "If acute carpal tunnel syndrome is noted, then surgical release of the carpal tunnel and fracture fixation should be performed urgently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 330, "offsetInEndSection": 464, "text": "If early carpal tunnel syndrome findings are noted during distal radius fracture management, all potential causes should be evaluated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}]}, {"id": "5a75f1f383b0d9ea66000006", "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26664519"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "LAF: Logic Alignment Free and its application to bacterial genomes classification.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 315, "offsetInEndSection": 511, "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 512, "offsetInEndSection": 689, "text": "This method searches for a minimal subset of k-mers whose relative frequencies are used to build classification models as disjunctive-normal-form logic formulas (if-then rules).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 690, "offsetInEndSection": 791, "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 971, "offsetInEndSection": 1235, "text": "State of the art methods to adjust the frequency of k-mers to the character distribution of the underlying genomes have negligible impact on classification performance, suggesting that the signal of each class is strong and that LAF is effective in identifying it.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 792, "offsetInEndSection": 970, "text": "In particular, we succeed in obtaining reliable classification at different taxonomic levels by extracting a handful of rules, each one based on the frequency of just few k-mers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 164, "offsetInEndSection": 314, "text": "Most of these algorithms rely on comparing the frequency of all the distinct substrings of fixed length (k-mers) that occur in the analyzed sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}]}, {"id": "5a722a052dc08e987e000002", "body": "Is Marfan syndrome associated with chordal rupture?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10441700", "http://www.ncbi.nlm.nih.gov/pubmed/14658812", "http://www.ncbi.nlm.nih.gov/pubmed/7790334", "http://www.ncbi.nlm.nih.gov/pubmed/18172522", "http://www.ncbi.nlm.nih.gov/pubmed/17317544"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 108, "offsetInEndSection": 314, "text": "This report gives a clinical and echocardiographic description of an infant with a mutation in exon 29 of the fibrillin-1 gene (FBN1), a region in which this severe form of Marfan syndrome seems to cluster.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Surgical management of mitral regurgitation in patients with Marfan syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 26, "offsetInEndSection": 257, "text": "STUDY: Although, in patients with Marfan syndrome, the most common cardiovascular abnormalities are aortic root dilatation and aortic valve regurgitation, mitral valve dysfunction is the most frequently accompanying cardiac lesion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 257, "offsetInEndSection": 479, "text": "METHODS: The clinical course and management is reported of nine patients (seven men, two women; mean age 29.2 +/- 2.3 years) with Marfan syndrome who required different mitral valve procedures and aortic valve replacement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 480, "offsetInEndSection": 639, "text": "Mitral regurgitation was caused by annulus dilatation in all patients, by leaflet prolapse in five patients, and by chordal rupture due to endocarditis in two.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 640, "offsetInEndSection": 770, "text": "Six patients underwent mitral valve replacement; three of these were operated on using preservation of the mitral valve apparatus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 771, "offsetInEndSection": 839, "text": "Three patients underwent mitral annuloplasty and chordal shortening.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Perioperative coronary artery spasm in modified Bentall's operation for annulo-aortic ectasia in Marfan's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334"}]}, {"id": "5a75f2fc83b0d9ea66000007", "body": "What is TCGA2BED?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049410"], "snippets": [{"offsetInBeginSection": 415, "offsetInEndSection": 579, "text": "RESULTS: We propose TCGA2BED a software tool to search and retrieve TCGA data, and convert them in the structured BED format for their seamless use and integration.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 666, "offsetInEndSection": 812, "text": "Furthermore, TCGA2BED extends TCGA data with information extracted from other genomic databases (i.e., NCBI Entrez Gene, HGNC, UCSC, and miRBase).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 1131, "offsetInEndSection": 1428, "text": "CONCLUSIONS: The availability of the valuable TCGA data in BED format reduces the time spent in taking advantage of them: it is possible to efficiently and effectively deal with huge amounts of cancer genomic data integratively, and to search, retrieve and extend them with additional information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 1429, "offsetInEndSection": 1636, "text": "The BED format facilitates the investigators allowing several knowledge discovery analyses on all tumor types in TCGA with the final aim of understanding pathological mechanisms and aiding cancer treatments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "BACKGROUND: Data extraction and integration methods are becoming essential to effectively access and take advantage of the huge amounts of heterogeneous genomics and clinical data increasingly available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 580, "offsetInEndSection": 665, "text": "Additionally, it supports the conversion in CSV, GTF, JSON, and XML standard formats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 5, "offsetInEndSection": 83, "text": "BED: extracting, extending, integrating, and querying The Cancer Genome Atlas.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 204, "offsetInEndSection": 415, "text": "In this work, we focus on The Cancer Genome Atlas, a comprehensive archive of tumoral data containing the results of high-throughout experiments, mainly Next Generation Sequencing, for more than 30 cancer types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}, {"offsetInBeginSection": 813, "offsetInEndSection": 1131, "text": "We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410"}]}, {"id": "5a722ccd2dc08e987e000003", "body": "What is the mechanism of action of Tezepelumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28877011"], "snippets": [{"offsetInBeginSection": 149, "offsetInEndSection": 492, "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 492, "offsetInEndSection": 673, "text": "METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 1130, "offsetInEndSection": 1260, "text": "Thus, exacerbation rates in the respective tezepelumab groups were lower by 61%, 71%, and 66% than the rate in the placebo group (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 1557, "offsetInEndSection": 1673, "text": "(Funded by MedImmune [a member of the AstraZeneca Group] and Amgen; PATHWAY ClinicalTrials.gov number, NCT02054130 .", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 781, "offsetInEndSection": 1129, "text": "RESULTS: The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high dose; 146 patients) resulted in annualized asthma exacerbation rates at week 52 of 0.26, 0.19, and 0.22, respectively, as compared with 0.67 in the placebo group (148 patients).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1556, "text": "PCONCLUSIONS: Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Tezepelumab in Adults with Uncontrolled Asthma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 674, "offsetInEndSection": 781, "text": "The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}, {"offsetInBeginSection": 1127, "offsetInEndSection": 1129, "text": ").", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011"}]}, {"id": "5a75f5aa83b0d9ea66000008", "body": "Describe JACUSA", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049429"], "snippets": [{"offsetInBeginSection": 866, "offsetInEndSection": 1027, "text": "RESULTS: We present JACUSA, a versatile one-stop solution to detect single nucleotide variant positions from comparing RNA-DNA and/or RNA-RNA sequencing samples.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1564, "text": "We further validated JACUSA's performance by testing its ability to detect A\u2192I events using sequencing data from a human cell culture experiment and publicly available RNA-seq data from Drosophila melanogaster heads.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1964, "offsetInEndSection": 2114, "text": "CONCLUSION: Our software JACUSA detects single nucleotide variants by comparing data from next-generation sequencing experiments (RNA-DNA or RNA-RNA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1147, "text": "The performance of JACUSA has been carefully evaluated and compared to other variant callers in an in silico benchmark.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 2115, "offsetInEndSection": 2294, "text": "In practice, JACUSA shows higher recall and comparable precision in detecting A\u2192I sites from RNA-DNA comparisons, while showing higher precision and recall in RNA-RNA comparisons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1828, "offsetInEndSection": 1964, "text": "Intriguingly, JACUSA captures most A\u2192I events from RRD comparisons of RNA sequencing data derived from Drosophila and HEK-293 data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "JACUSA: site-specific identification of RNA editing events from replicate sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1148, "offsetInEndSection": 1275, "text": "JACUSA outperforms other algorithms in terms of the F measure, which combines precision and recall, in all benchmark scenarios.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 663, "offsetInEndSection": 866, "text": "Even more surprising, condition-specific editing events, which would show up as differences in RNA-RNA comparisons (RRDs) and depend on particular cellular states, are rarely discussed in the literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1707, "offsetInEndSection": 1827, "text": "JACUSA has a higher recall and comparable precision for detecting true editing sites in RDD comparisons of HEK-293 data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}]}, {"id": "5a722d9f2dc08e987e000004", "body": "What is mechanism of action of Benralizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27119985", "http://www.ncbi.nlm.nih.gov/pubmed/27097165", "http://www.ncbi.nlm.nih.gov/pubmed/25306557", "http://www.ncbi.nlm.nih.gov/pubmed/28109128", "http://www.ncbi.nlm.nih.gov/pubmed/29086236", "http://www.ncbi.nlm.nih.gov/pubmed/28530840", "http://www.ncbi.nlm.nih.gov/pubmed/28919200", "http://www.ncbi.nlm.nih.gov/pubmed/23866823", "http://www.ncbi.nlm.nih.gov/pubmed/28737051", "http://www.ncbi.nlm.nih.gov/pubmed/25208464"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5R\u03b1, in Uncontrolled Eosinophilic Asthma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 482, "offsetInEndSection": 618, "text": "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 619, "offsetInEndSection": 801, "text": "In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 802, "offsetInEndSection": 905, "text": "Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 329, "offsetInEndSection": 451, "text": "We conducted a phase 2a study in South Korea and Japan to evaluate the effect of benralizumab in an East Asian population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 452, "offsetInEndSection": 699, "text": "The primary objective was to evaluate the effect of benralizumab in adults with uncontrolled eosinophilic asthma with 2-6 incidences of exacerbations in the past year using a medium/high dose of inhaled corticosteroids and long-acting \u03b22-agonists.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 1092, "offsetInEndSection": 1248, "text": "RESULTS: The asthma exacerbation rate was reduced by 33, 45 or 36% versus the placebo group when treated with 2, 20 or 100 mg of benralizumab, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1385, "text": "The percent mean change in forced expiratory volume at 1 s increased with each of the three doses in subjects treated with benralizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 103, "offsetInEndSection": 342, "text": "In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils, in adults with uncontrolled eosinophilic asthma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25306557"}]}, {"id": "5a75f6e083b0d9ea66000009", "body": "Which data simulator is available for CLIP-SEQ experiments?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26776207"], "snippets": [{"offsetInBeginSection": 5, "offsetInEndSection": 58, "text": "SIMULATOR: A DATA SIMULATOR FOR CLIP-SEQ EXPERIMENTS.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 195, "offsetInEndSection": 324, "text": "Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 325, "offsetInEndSection": 457, "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 458, "offsetInEndSection": 582, "text": "This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 583, "offsetInEndSection": 715, "text": "To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 846, "offsetInEndSection": 1024, "text": "In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1150, "text": "These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 114, "offsetInEndSection": 194, "text": "For the processing of the resulting short read data, various tools are utilized.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 716, "offsetInEndSection": 845, "text": "This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}]}, {"id": "5a72302b2dc08e987e000005", "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29090661", "http://www.ncbi.nlm.nih.gov/pubmed/28222987", "http://www.ncbi.nlm.nih.gov/pubmed/10847965", "http://www.ncbi.nlm.nih.gov/pubmed/27872317", "http://www.ncbi.nlm.nih.gov/pubmed/2940526", "http://www.ncbi.nlm.nih.gov/pubmed/26808286", "http://www.ncbi.nlm.nih.gov/pubmed/18559363", "http://www.ncbi.nlm.nih.gov/pubmed/17704480"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "French multicenter experience with the GORE TIGRIS Vascular Stent in superficial femoral and popliteal arteries.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "BACKGROUND: Preliminary results in small single-center studies after stenting with the GORE TIGRIS Vascular Stent (W.\u00a0L.\u00a0Gore & Associates, Flagstaff, Ariz) show promising short-term primary patency rates, but larger, multicenter studies are needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 250, "offsetInEndSection": 426, "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 426, "offsetInEndSection": 746, "text": "METHODS: This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1219, "text": "RESULTS: The GORE TIGRIS Vascular Stent was used to successfully treat 239 lesions, of which 141 lesions were located in the superficial femoral artery and 98 in the popliteal artery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 1499, "offsetInEndSection": 1732, "text": "CONCLUSIONS: Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The aim of the present study was to evaluate the clinical results at 3 years following treating intrabony periodontal defects with different nonresorbable and bioabsorbable membrane barriers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847965"}, {"offsetInBeginSection": 306, "offsetInEndSection": 554, "text": "Twenty pockets were treated with Gore Resolut, a bioabsorbable membrane; 20 were treated with Gore-Tex, a titanium-reinforced membrane; and 20 with nonresorbable Gore-Tex membrane (all manufactured by Gore Regenerative Technologies, Flagstaff, AZ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847965"}, {"offsetInBeginSection": 555, "offsetInEndSection": 757, "text": "The therapeutic results were evaluated by assessing probing pocket depth (PPD), recession of the gingival margin (GR), and clinical attachment level (CAL) at baseline, at 1 and at 3 years after therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847965"}]}, {"id": "5a760e5583b0d9ea66000018", "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028265"], "snippets": [{"offsetInBeginSection": 258, "offsetInEndSection": 499, "text": "Therefore, statistical algorithms to perform spatial, genome-wide correlation among genomic features are required.Results: Here, we propose a method, StereoGene, that rapidly estimates genome-wide correlation among pairs of genomic features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1211, "text": "We apply our method to numerous comparisons of ChIP-Seq datasets from the Human Epigenome Atlas and FANTOM CAGE to demonstrate its wide applicability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 1472, "offsetInEndSection": 1888, "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.Availability and implementation: The StereoGene C\u2009++\u2009source code, program documentation, Galaxy integration scripts and examples are available from the project homepage http://stereogene.bioinf.fbb.msu.ru/.Contact: favorov@sensi.org.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 839, "offsetInEndSection": 977, "text": "Representing the correlation as a function of the genome position, StereoGene outputs the local correlation track as part of the analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Motivation: Genomics features with similar genome-wide distributions are generally hypothesized to be functionally related, for example, colocalization of histones and transcription start sites indicate chromatin regulation of transcription factor activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 634, "offsetInEndSection": 750, "text": "StereoGene enables correlation of continuous data directly, avoiding the data binarization and subsequent data loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 978, "offsetInEndSection": 1060, "text": "StereoGene also accounts for confounders such as input DNA by partial correlation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "StereoGene: rapid estimation of genome-wide correlation of continuous or interval feature data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 500, "offsetInEndSection": 633, "text": "These features may represent high-throughput data mapped to reference genome or sets of genomic annotations in that reference genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 751, "offsetInEndSection": 838, "text": "Correlations are computed among neighboring genomic positions using kernel correlation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}]}, {"id": "5a72329e2dc08e987e000006", "body": "Falciform ligament sign is characteristic to which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23133059", "http://www.ncbi.nlm.nih.gov/pubmed/16807665", "http://www.ncbi.nlm.nih.gov/pubmed/19716250", "http://www.ncbi.nlm.nih.gov/pubmed/26577973", "http://www.ncbi.nlm.nih.gov/pubmed/2003436", "http://www.ncbi.nlm.nih.gov/pubmed/17322659", "http://www.ncbi.nlm.nih.gov/pubmed/3881894", "http://www.ncbi.nlm.nih.gov/pubmed/907474", "http://www.ncbi.nlm.nih.gov/pubmed/2910743", "http://www.ncbi.nlm.nih.gov/pubmed/27938473"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Perivascular epithelioid cell tumor (PEComa) of falciform ligament - an extremely rare tumor.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Primary tumor of falciform ligament is exceedingly uncommon.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 322, "offsetInEndSection": 421, "text": "Here, we report a case of PEComa of falciform ligament, which presented with a huge abdominal lump.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "INTRODUCTION: Hydatid disease is a common condition worldwide and continues to be a significant societal problem in many countries of all continents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 150, "offsetInEndSection": 273, "text": "Alhough other treatment options are also available, surgery remains the cornerstone of therapy for hepatic hydatid disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 428, "offsetInEndSection": 617, "text": "Therefore we describe a new technique using the falciform ligament as a flap instead of omentum for managing the residual cavity, as it is more anatomic and a better option for liver cysts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 617, "offsetInEndSection": 815, "text": "METHODS: From April 2004 to October 2005, a total of 20 patients (11 women) with a median age of 43 years (range 23-66 years) underwent partial cystectomy-falciformoplasty for hydatid liver disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 1730, "offsetInEndSection": 1863, "text": "US did not reveal any collection, the cavities were fully collapsed, and blood flow to the falciform ligaments was seen to be viable.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 2019, "offsetInEndSection": 2084, "text": "It might be a good choice in patients with hydatid liver disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "What determines the periportal free air, and ligamentum teres and falciform ligament signs on CT: can these specific air distributions be valuable predictors of gastroduodenal perforation?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250"}]}]}